CA3022294A1 - Method and system for characterizing skin-related conditions - Google Patents
Method and system for characterizing skin-related conditions Download PDFInfo
- Publication number
- CA3022294A1 CA3022294A1 CA3022294A CA3022294A CA3022294A1 CA 3022294 A1 CA3022294 A1 CA 3022294A1 CA 3022294 A CA3022294 A CA 3022294A CA 3022294 A CA3022294 A CA 3022294A CA 3022294 A1 CA3022294 A1 CA 3022294A1
- Authority
- CA
- Canada
- Prior art keywords
- kegg
- derived feature
- feature
- skin
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 175
- 244000005700 microbiome Species 0.000 claims abstract description 313
- 238000012512 characterization method Methods 0.000 claims abstract description 236
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 196
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 238000012163 sequencing technique Methods 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 10
- 241000894007 species Species 0.000 claims description 102
- 230000004060 metabolic process Effects 0.000 claims description 73
- 239000012472 biological sample Substances 0.000 claims description 53
- 238000012545 processing Methods 0.000 claims description 43
- 230000015572 biosynthetic process Effects 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 230000015556 catabolic process Effects 0.000 claims description 24
- 230000002068 genetic effect Effects 0.000 claims description 23
- 201000004624 Dermatitis Diseases 0.000 claims description 22
- 206010013786 Dry skin Diseases 0.000 claims description 22
- 238000006731 degradation reaction Methods 0.000 claims description 22
- 230000037336 dry skin Effects 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 21
- 238000009258 post-therapy Methods 0.000 claims description 21
- 208000010668 atopic eczema Diseases 0.000 claims description 20
- 210000004761 scalp Anatomy 0.000 claims description 20
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 230000003321 amplification Effects 0.000 claims description 18
- 230000001737 promoting effect Effects 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 206010000496 acne Diseases 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 16
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 15
- 241001156739 Actinobacteria <phylum> Species 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 230000036211 photosensitivity Effects 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- 241001148536 Bacteroides sp. Species 0.000 claims description 12
- 208000001840 Dandruff Diseases 0.000 claims description 11
- 241001112724 Lactobacillales Species 0.000 claims description 9
- 241000186429 Propionibacterium Species 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 241000192125 Firmicutes Species 0.000 claims description 8
- 241000191940 Staphylococcus Species 0.000 claims description 8
- 241000194017 Streptococcus Species 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 241000605059 Bacteroidetes Species 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 7
- 241000193833 Bacillales Species 0.000 claims description 6
- 241001081257 Erysipelotrichales Species 0.000 claims description 6
- 241001081259 Erysipelotrichia Species 0.000 claims description 6
- 241000295644 Staphylococcaceae Species 0.000 claims description 6
- 241001147693 Staphylococcus sp. Species 0.000 claims description 6
- 241000194018 Streptococcaceae Species 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- -1 cyanoamino Chemical group 0.000 claims description 6
- 238000010801 machine learning Methods 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 241001046559 Marvinbryantia Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 230000032258 transport Effects 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 241000099223 Alistipes sp. Species 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 241000606215 Bacteroides vulgatus Species 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 241000186216 Corynebacterium Species 0.000 claims description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 241001521757 Propionibacterium sp. Species 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 230000036267 drug metabolism Effects 0.000 claims description 4
- 230000037149 energy metabolism Effects 0.000 claims description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- 230000037356 lipid metabolism Effects 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000029553 photosynthesis Effects 0.000 claims description 4
- 238000010672 photosynthesis Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 241000909284 Acidaminococcaceae Species 0.000 claims description 3
- 241000701474 Alistipes Species 0.000 claims description 3
- 241001227086 Anaerostipes Species 0.000 claims description 3
- 241001013579 Anaerotruncus Species 0.000 claims description 3
- 241000606126 Bacteroidaceae Species 0.000 claims description 3
- 241000692822 Bacteroidales Species 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 3
- 241001141113 Bacteroidia Species 0.000 claims description 3
- 241001135755 Betaproteobacteria Species 0.000 claims description 3
- 241001495171 Bilophila Species 0.000 claims description 3
- 241001202853 Blautia Species 0.000 claims description 3
- 241001600148 Burkholderiales Species 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 241001112696 Clostridia Species 0.000 claims description 3
- 241001430149 Clostridiaceae Species 0.000 claims description 3
- 241001112695 Clostridiales Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 241001464956 Collinsella Species 0.000 claims description 3
- 241001657523 Coriobacteriaceae Species 0.000 claims description 3
- 241001662464 Coriobacteriales Species 0.000 claims description 3
- 241000186031 Corynebacteriaceae Species 0.000 claims description 3
- 241001467894 Desulfovibrionaceae Species 0.000 claims description 3
- 241001571085 Desulfovibrionales Species 0.000 claims description 3
- 241001143779 Dorea Species 0.000 claims description 3
- 241000089032 Erysipelatoclostridium Species 0.000 claims description 3
- 241000609971 Erysipelotrichaceae Species 0.000 claims description 3
- 241001608234 Faecalibacterium Species 0.000 claims description 3
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims description 3
- 241000244332 Flavobacteriaceae Species 0.000 claims description 3
- 241001141128 Flavobacteriales Species 0.000 claims description 3
- 241000230562 Flavobacteriia Species 0.000 claims description 3
- 241000662772 Flavonifractor Species 0.000 claims description 3
- 241000192128 Gammaproteobacteria Species 0.000 claims description 3
- 241000089024 Intestinibacter Species 0.000 claims description 3
- 241001134638 Lachnospira Species 0.000 claims description 3
- 241001112693 Lachnospiraceae Species 0.000 claims description 3
- 241000909283 Negativicutes Species 0.000 claims description 3
- 241000785902 Odoribacter Species 0.000 claims description 3
- 241001607451 Oscillospiraceae Species 0.000 claims description 3
- 241000160321 Parabacteroides Species 0.000 claims description 3
- 241000606752 Pasteurellaceae Species 0.000 claims description 3
- 241000947860 Pasteurellales Species 0.000 claims description 3
- 241001464921 Phascolarctobacterium Species 0.000 claims description 3
- 241000692843 Porphyromonadaceae Species 0.000 claims description 3
- 241000605861 Prevotella Species 0.000 claims description 3
- 241000692844 Prevotellaceae Species 0.000 claims description 3
- 241000192142 Proteobacteria Species 0.000 claims description 3
- 241000202386 Pseudobutyrivibrio Species 0.000 claims description 3
- 241000692845 Rikenellaceae Species 0.000 claims description 3
- 241000605947 Roseburia Species 0.000 claims description 3
- 241000095588 Ruminococcaceae Species 0.000 claims description 3
- 241000192023 Sarcina Species 0.000 claims description 3
- 241000909295 Selenomonadales Species 0.000 claims description 3
- 241001136694 Subdoligranulum Species 0.000 claims description 3
- 241000123710 Sutterella Species 0.000 claims description 3
- 241000813827 Sutterellaceae Species 0.000 claims description 3
- 241000089063 Terrisporobacter Species 0.000 claims description 3
- 241001148134 Veillonella Species 0.000 claims description 3
- 241001430183 Veillonellaceae Species 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- INAPMGSXUVUWAF-UHFFFAOYSA-L (2,3,4,5,6-pentahydroxycyclohexyl) phosphate Chemical compound OC1C(O)C(O)C(OP([O-])([O-])=O)C(O)C1O INAPMGSXUVUWAF-UHFFFAOYSA-L 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- XEQLFNPSYWZPOW-NUOYRARPSA-N (2r)-4-amino-n-[(1r,2s,3r,4r,5s)-5-amino-4-[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)O)NC(=O)[C@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N XEQLFNPSYWZPOW-NUOYRARPSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 2
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims description 2
- 241000203809 Actinomycetales Species 0.000 claims description 2
- 102000014777 Adipokines Human genes 0.000 claims description 2
- 108010078606 Adipokines Proteins 0.000 claims description 2
- 241001135230 Alistipes putredinis Species 0.000 claims description 2
- 241000099174 Anaerostipes sp. Species 0.000 claims description 2
- 241000304886 Bacilli Species 0.000 claims description 2
- 241001674039 Bacteroides acidifaciens Species 0.000 claims description 2
- 241000217846 Bacteroides caccae Species 0.000 claims description 2
- 241000606124 Bacteroides fragilis Species 0.000 claims description 2
- 241001220441 Bacteroides plebeius Species 0.000 claims description 2
- 241001430332 Bifidobacteriaceae Species 0.000 claims description 2
- 241001655328 Bifidobacteriales Species 0.000 claims description 2
- 241000335561 Blautia faecis Species 0.000 claims description 2
- 241000028537 Blautia luti Species 0.000 claims description 2
- 241000772275 Blautia sp. Species 0.000 claims description 2
- 241000335560 Blautia stercoris Species 0.000 claims description 2
- 241001038648 Blautia wexlerae Species 0.000 claims description 2
- 229930183180 Butirosin Natural products 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 241001262170 Collinsella aerofaciens Species 0.000 claims description 2
- 241000186249 Corynebacterium sp. Species 0.000 claims description 2
- 241001098119 Corynebacterium spheniscorum Species 0.000 claims description 2
- 241000918600 Corynebacterium ulcerans Species 0.000 claims description 2
- 241000186427 Cutibacterium acnes Species 0.000 claims description 2
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- 101710160937 DNA replication protein Proteins 0.000 claims description 2
- 241001135761 Deltaproteobacteria Species 0.000 claims description 2
- 241001535083 Dialister Species 0.000 claims description 2
- 241001531200 Dorea formicigenerans Species 0.000 claims description 2
- 241000016537 Dorea longicatena Species 0.000 claims description 2
- 239000005792 Geraniol Substances 0.000 claims description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 241001134642 Lachnospira pectinoschiza Species 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 2
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 2
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 102000007462 Molecular Motor Proteins Human genes 0.000 claims description 2
- 108010085191 Molecular Motor Proteins Proteins 0.000 claims description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims description 2
- 241001135232 Odoribacter splanchnicus Species 0.000 claims description 2
- 241000606210 Parabacteroides distasonis Species 0.000 claims description 2
- 241000204306 Parabacteroides merdae Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 108010013639 Peptidoglycan Proteins 0.000 claims description 2
- 241001112692 Peptostreptococcaceae Species 0.000 claims description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 2
- 241001464924 Phascolarctobacterium faecium Species 0.000 claims description 2
- 241000711849 Phascolarctobacterium sp. Species 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 102000019337 Prenyltransferases Human genes 0.000 claims description 2
- 108050006837 Prenyltransferases Proteins 0.000 claims description 2
- 208000031951 Primary immunodeficiency Diseases 0.000 claims description 2
- 241001430313 Propionibacteriaceae Species 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 101710198868 Recombination and repair protein Proteins 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000398180 Roseburia intestinalis Species 0.000 claims description 2
- 241001394655 Roseburia inulinivorans Species 0.000 claims description 2
- 241000711837 Roseburia sp. Species 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 241000194022 Streptococcus sp. Species 0.000 claims description 2
- 241000302468 Streptococcus sp. BS35a Species 0.000 claims description 2
- 241000096522 Streptococcus sp. oral taxon G59 Species 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 241001580973 Subdoligranulum variabile Species 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 241000644554 Sutterella stercoricanis Species 0.000 claims description 2
- 241000123713 Sutterella wadsworthensis Species 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 241001261005 Verrucomicrobia Species 0.000 claims description 2
- 241000607626 Vibrio cholerae Species 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 150000001348 alkyl chlorides Chemical class 0.000 claims description 2
- 230000037354 amino acid metabolism Effects 0.000 claims description 2
- 229940064734 aminobenzoate Drugs 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 230000033590 base-excision repair Effects 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229950004527 butirosin Drugs 0.000 claims description 2
- 235000021258 carbohydrate absorption Nutrition 0.000 claims description 2
- 235000021257 carbohydrate digestion Nutrition 0.000 claims description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000032823 cell division Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000009087 cell motility Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000033077 cellular process Effects 0.000 claims description 2
- 230000005754 cellular signaling Effects 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 230000035605 chemotaxis Effects 0.000 claims description 2
- 229930002875 chlorophyll Natural products 0.000 claims description 2
- 235000019804 chlorophyll Nutrition 0.000 claims description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 229940113087 geraniol Drugs 0.000 claims description 2
- 230000004110 gluconeogenesis Effects 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 230000037362 glycan biosynthesis Effects 0.000 claims description 2
- 230000037347 glycan metabolism Effects 0.000 claims description 2
- 150000002313 glycerolipids Chemical class 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- 230000034659 glycolysis Effects 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000010365 information processing Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 230000009061 membrane transport Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000037340 metabolism of cofactors and vitamins Effects 0.000 claims description 2
- 230000037344 metabolism of terpenoids and polyketides Effects 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 230000033607 mismatch repair Effects 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 230000003121 nonmonotonic effect Effects 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- 229960002950 novobiocin Drugs 0.000 claims description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000037360 nucleotide metabolism Effects 0.000 claims description 2
- 230000020520 nucleotide-excision repair Effects 0.000 claims description 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 2
- 229940014662 pantothenate Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 230000004108 pentose phosphate pathway Effects 0.000 claims description 2
- 210000002824 peroxisome Anatomy 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229930015704 phenylpropanoid Natural products 0.000 claims description 2
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 230000000243 photosynthetic effect Effects 0.000 claims description 2
- 229930000732 piperidine alkaloid Natural products 0.000 claims description 2
- 244000000003 plant pathogen Species 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- 229940055019 propionibacterium acne Drugs 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 230000012846 protein folding Effects 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 230000004144 purine metabolism Effects 0.000 claims description 2
- 229930002371 pyridine alkaloid Natural products 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 230000028706 ribosome biogenesis Effects 0.000 claims description 2
- 229930000044 secondary metabolite Natural products 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000028070 sporulation Effects 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 claims description 2
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 claims description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 2
- 229930004668 tropane alkaloid Natural products 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 229940118696 vibrio cholerae Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000002676 xenobiotic agent Substances 0.000 claims description 2
- 229940023877 zeatin Drugs 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 108010052832 Cytochromes Proteins 0.000 claims 1
- 230000008569 process Effects 0.000 description 60
- 230000006870 function Effects 0.000 description 34
- 239000006041 probiotic Substances 0.000 description 30
- 235000018291 probiotics Nutrition 0.000 description 30
- 230000000529 probiotic effect Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 19
- 230000036541 health Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 11
- 241001515965 unidentified phage Species 0.000 description 11
- 230000002596 correlated effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000013459 approach Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000012549 training Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 208000027244 Dysbiosis Diseases 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000007140 dysbiosis Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 241000736262 Microbiota Species 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 244000005702 human microbiome Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 206010035043 Pilonidal cyst Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- VOJUXHHACRXLTD-UHFFFAOYSA-N 1,4-dihydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC(O)=C21 VOJUXHHACRXLTD-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010305 Epidermal Cyst Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010034016 Paronychia Diseases 0.000 description 2
- 208000000528 Pilonidal Sinus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 229920000617 arabinoxylan Polymers 0.000 description 2
- 150000004783 arabinoxylans Chemical class 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011338 personalized therapy Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- VOJUXHHACRXLTD-UHFFFAOYSA-M 1,4-dihydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=CC(C([O-])=O)=C(O)C2=C1 VOJUXHHACRXLTD-UHFFFAOYSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108010065780 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase Proteins 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241001226430 Bacillus polyfermenticus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004194 Bed bug infestation Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000863012 Caulobacter Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241001327638 Cimex lectularius Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000002078 Ingrown Nails Diseases 0.000 description 1
- 206010052899 Ingrown hair Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000007993 Kaposi Varicelliform Eruption Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241001299661 Prevotella bryantii Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000204115 Sporolactobacillus inulinus Species 0.000 description 1
- 241000439819 Sporolactobacillus vineae Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 1
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940104704 bacillus polyfermenticus Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000009226 cognitive therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 108010089355 dihydroneopterin aldolase Proteins 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 208000013046 dyshidrosis Diseases 0.000 description 1
- 206010014197 eczema herpeticum Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 208000017338 epidermoid cysts Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000003779 seborrheic infantile dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Data Mining & Analysis (AREA)
- Zoology (AREA)
- Theoretical Computer Science (AREA)
- Wood Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Embodiments of a method and system for characterizing a skin-related condition in relation to a user can include one or more of: a handling network operable to collect containers comprising material from a set of users, the handling network comprising a sequencing system operable to determine microorganism sequences from sequencing the material; a microbiome characterization system operable to: determine at least one of microbiome composition data and microbiome functional diversity data based on the microorganism sequences, collect supplementary data associated with the skin-related condition for the set of users, and transform the supplementary data and the at least one of the microbiome composition data and the microbiome functional diversity data into a characterization model; and a therapy system operable to promote a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
Description
METHOD AND SYSTEM FOR CHARACTERIZING SKIN-RELATED CONDITIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001 ] This application additionally claims the benefit of U.S. Provisional Application serial number 62/327,048, filed 25-APR-2016, U.S. Provisional Application serial number 62/327,089, filed 25-APR-2016, and U.S. Provisional Application serial number 62/327,126, filed 25-APR-2016, which are each incorporated in their entirety by this reference.
TECHNICAL FIELD
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001 ] This application additionally claims the benefit of U.S. Provisional Application serial number 62/327,048, filed 25-APR-2016, U.S. Provisional Application serial number 62/327,089, filed 25-APR-2016, and U.S. Provisional Application serial number 62/327,126, filed 25-APR-2016, which are each incorporated in their entirety by this reference.
TECHNICAL FIELD
[0002] This invention relates generally to the field of microbiology and more specifically to a new and useful method and system for characterizing skin-related conditions in the field of microbiology.
BACKGROUND
BACKGROUND
[0003] A microbiome is an ecological community of commensal, symbiotic, and pathogenic microorganisms that are associated with an organism. The human microbiome includes over 10 times more microbial cells than human cells, but characterization of the human microbiome is still in nascent stages due to limitations in sample processing techniques, genetic analysis techniques, and resources for processing large amounts of data. Nonetheless, the microbiome is suspected to play at least a partial role in a number of health/disease-related states (e.g., preparation for childbirth, diabetes, autoimmune disorders, gastrointestinal disorders, rheumatoid disorders, neurological disorders, etc.). Given the profound implications of the microbiome in affecting a user's health, efforts related to the characterization of the microbiome, the generation of insights from the characterization, and the generation of therapeutics configured to rectify states of dysbiosis should be pursued. Current methods and systems for analyzing the microbiomes of humans and providing therapeutic measures based on gained insights have, however, left many questions unanswered. In particular, methods for characterizing certain health conditions and therapies (e.g., probiotic
4 PCT/US2017/029470 therapies) tailored to specific users based upon microbiome composition and/or functional features have not been viable due to limitations in current technologies.
[0004] As such, there is a need in the field of microbiology for a new and useful method and system for characterizing health conditions in an individualized and population-wide manner. This invention creates such a new and useful method and system.
BRIEF DESCRIPTION OF THE FIGURES
[0004] As such, there is a need in the field of microbiology for a new and useful method and system for characterizing health conditions in an individualized and population-wide manner. This invention creates such a new and useful method and system.
BRIEF DESCRIPTION OF THE FIGURES
[0005] FIGURES 1A-1B are flowchart representations of variations of embodiments of a method for microbiome characterization;
[0006] FIGURE 2 depicts variations of embodiments of a system and method for microbiome characterization;
[0007] FIGURE 3 depicts a schematic representation of a variation of generating and applying a characterization model in an embodiment of a method for microbiome characterization;
[0008] FIGURE 4 depicts a variation of applying and updating a characterization model and a therapy model in an embodiment of a method for microbiome characterization;
[0009] FIGURE 5 depicts a variation of applying multiple characterization models in an embodiment of a method for microbiome characterization;
[0010] FIGURE 6 depicts a variation of promoting therapies in variations of an embodiment of a method for microbiome characterization;
[0011] FIGURE 7 depicts variations of mechanisms by which probiotic-based therapies operate in an embodiment of a method for microbiome characterization;
[0012] FIGURE 8 depicts a variation of notification provision in an embodiment of a method for microbiome characterization;
[0013] FIGURE 9 depicts a variation of an interface for providing skin-related condition information in an embodiment of a method for microbiome characterization;
[0014] FIGURE 10 depicts variations of notification provision in an embodiment of a method for microbiome characterization;
[0015] FIGURE ii depicts a variation of notification provision in an embodiment of a method for microbiome characterization; and
[0016] FIGURE 12 depicts a variation of sample processing parameter modification in an embodiment of a method for microbiome characterization.
DESCRIPTION OF THE EMBODIMENTS
DESCRIPTION OF THE EMBODIMENTS
[0017] The following description of the embodiments of the invention is not intended to limit the invention to these embodiments, but rather to enable any person skilled in the art to make and use this invention.
1. Overview.
1. Overview.
[0018]As shown in FIGURE 2, embodiments of a system 200 for characterizing (e.g., evaluating) a skin-related condition in relation to a user (e.g., a human subject, an animal subject, etc.) can include one or more of: a handling network 210 operable to collect containers including material from a set of users (e.g., a population of users), the handling network 210 including a sequencing system operable to determine microorganism sequences from sequencing the material; a microbiome characterization system 220 operable to: determine at least one of microbiome composition data and microbiome functional diversity data based on the microorganism sequences, collect supplementary data associated with the skin-related condition for the set of users, and transform the supplementary data and features extracted from the at least one of the microbiome composition data and the microbiome functional diversity data into a characterization model for the skin-related condition; and a therapy system 230 (e.g., treatment system) operable to promote a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
[0019] The system 200 and method 100 can function to generate models that can be used to characterize and/or diagnose users according to at least one of their microbiome composition and functional features (e.g., as a clinical diagnostic, as a companion diagnostic, etc.); provide therapeutic measures (e.g., probiotic-based therapeutic measures, phage-based therapeutic measures, small-molecule-based therapeutic measures, clinical measures, etc.) to users based upon microbiome analysis for a population of users; and/or perform any suitable function.
[0020] The system 200 and method 100 can preferably generate and promote characterizations and therapies for skin-related conditions, which can include any one or more of skin-related: symptoms, causes, diseases, disorders, and/or any other suitable aspects associated with skin-related conditions. Skin-related conditions can include any one or more of: eczema (e.g., atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, stasis dermatitis, acrodermatitis, seborrhoeic eczema, xerotic eczema, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis, neurodermatitis, autoeczematization, eczema herpeticum, etc.), dry skin, a scalp-related condition (e.g., dandruff, hair loss, cradle cap, scalp-related, head lice, ringworm, folliculitis, scalp psoriasis, etc.), photosensitivity (e.g., photoallergy, phototoxicity, etc.), a pimple-related condition(e.g., pimples, papules, nodules, epidermoid cysts, sebaceous cysts, pilonidal cyst, other cysts, pilonidal abscess, pustules, blackheads, whiteheads, acne-associated pus, other acne-associated conditions, etc.), rosacea, oily skin, skin cancer, lupus, rubeola, psoriasis, cold sores, hemangioma, hives, shingles, pemphigoid, tinea versicolor, corns, calluses, ulcers (e.g., decubitus ulcers, leg ulcers, etc.), keloid, lichen planus, actinic keratosis, pilonidal sinus, seborrheic keratosis, ingrown nails, ingrown hairs, canker sores, herpes stomatitis, fungal nail infection, ichthyosis vulgaris, dermatomyositis, molluscum contagiosum, cutis laxa, erysipelas, rash (e.g., diaper rash), dyshidrotic eczema, canker sores, impetigo, necrotizing fasciitis, cutaneous candidiasis, carbuncle, cellulitis, hypohidrosis, hyperhidrosis, warts (e.g., plantar warts, palmer warts, etc.), blisters, chafing, sunburn, Muehrcke's lines, varicose veins, lice, scabies, plant-related skin-related conditions (e.g., rashes associated with poison ivy, oak, sumac, etc.), bruises, bedbug-associated conditions, lumps, itching, vitiligo, leprosy, boils, staph infection, athlete's foot, sporotrichosis, fungal nail infection, shingles, chickenpox, other bacterial skin infections, other fungal skin infections, and/or any other suitable skin-related conditions.
[0021] One or more instances of the method 100 and/or processes described herein can be performed asynchronously (e.g., sequentially), concurrently (e.g., in parallel;
concurrently on different threads for parallel computing to improve system processing ability for determining and/or providing characterizations and/or therapies for skin-related conditions; etc.), in temporal relation to a trigger event, and/or in any other suitable order at any suitable time and frequency by and/or using one or more instances of the system 200, elements, and/or entities described herein. However, the method 100 and/or system 200 can be configured in any suitable manner.
2. Benefits
concurrently on different threads for parallel computing to improve system processing ability for determining and/or providing characterizations and/or therapies for skin-related conditions; etc.), in temporal relation to a trigger event, and/or in any other suitable order at any suitable time and frequency by and/or using one or more instances of the system 200, elements, and/or entities described herein. However, the method 100 and/or system 200 can be configured in any suitable manner.
2. Benefits
[0022] Microbiome analysis can enable accurate and efficient characterization and/or therapy provision for skin-related conditions caused by and/or otherwise associated with microorganisms. The technology can overcome several challenges faced by conventional approaches in characterizing and/or promoting therapies for skin-related conditions. First, conventional approaches can require patients to visit a care provider who performs a physical inspection in relation to skin-related conditions.
Second, conventional genetic sequencing and analysis technologies for human genome sequencing can be incompatible and/or inefficient when applied to the microbiome (e.g., where the human microbiome can include over 10 times more microbial cells than human cells; where optimal sample processing techniques can differ; where sequence reference databases can differ; where microbiome characterization can include accounting for the different compositions and functional diversity of the microbiome across populations; where the microbiome can vary across different body regions of the user; etc.). Third, the onset of sequencing technologies (e.g., next-generation sequencing) has given rise to technological issues (e.g., data processing issues, information display issues, microbiome analysis issues, therapy prediction issues, therapy provision issues, etc.) that would not exist but for the unprecedented advances in speed and data generation associated with sequencing genetic material.
Examples of the system 200 and the method 100 can confer technologically-rooted solutions to at least the challenges described above.
Second, conventional genetic sequencing and analysis technologies for human genome sequencing can be incompatible and/or inefficient when applied to the microbiome (e.g., where the human microbiome can include over 10 times more microbial cells than human cells; where optimal sample processing techniques can differ; where sequence reference databases can differ; where microbiome characterization can include accounting for the different compositions and functional diversity of the microbiome across populations; where the microbiome can vary across different body regions of the user; etc.). Third, the onset of sequencing technologies (e.g., next-generation sequencing) has given rise to technological issues (e.g., data processing issues, information display issues, microbiome analysis issues, therapy prediction issues, therapy provision issues, etc.) that would not exist but for the unprecedented advances in speed and data generation associated with sequencing genetic material.
Examples of the system 200 and the method 100 can confer technologically-rooted solutions to at least the challenges described above.
[0023] First, the technology can confer improvements in computer-related technology (e.g., artificial intelligence, machine learning, biological sample processing and computational analysis network, etc.) by facilitating computer performance of functions not previously performable. For example, the technology can computationally generate microbiome characterizations and recommended therapies for skin-related conditions, based on microbiome sequence datasets and microorganism reference sequence databases (e.g., Genome Reference Consortium) that are recently viable due to advances in sample processing techniques and sequencing technology.
[0024] Second, the technology can confer improvements in processing speed, microbiome characterization accuracy, microbiome-related therapy determination and promotion, and/or other suitable aspects in relation to skin-related conditions. The technology can generate and apply skin-related feature-selection rules to select an optimized subset of features (e.g., microbiome composition features, microbiome functional diversity features, etc.) out of a vast potential pool of features (e.g., extractable from the plethora of microbiome data) for generating and applying characterization models and/or therapy models. The potential size of microbiomes (e.g., human microbiomes, animal microbiomes, etc.) can translate into a plethora of data, giving rise to questions of how to process and analyze the vast array of data to generate actionable microbiome insights in relation to skin-related conditions.
However, the skin-related feature-selection rules and associated technology can enable shorter training and execution times (e.g., for predictive machine learning models), model simplification facilitating efficient interpretation of results, reduction in overfitting, improvements in data sources (e.g., for collecting and processing microbiome datasets), improvements in identifying and presenting skin-related condition insights in relation to the microbiome, and other suitable improvements to facilitate rapid determination of characterizations and/or therapies.
However, the skin-related feature-selection rules and associated technology can enable shorter training and execution times (e.g., for predictive machine learning models), model simplification facilitating efficient interpretation of results, reduction in overfitting, improvements in data sources (e.g., for collecting and processing microbiome datasets), improvements in identifying and presenting skin-related condition insights in relation to the microbiome, and other suitable improvements to facilitate rapid determination of characterizations and/or therapies.
[0025] Third, the technology can transform entities (e.g., users, biological samples, therapy systems including medical devices, etc.) into different states or things. For example, the system 200 and/or method loo can identify therapies to promote to a patient to modify microbiome composition and/or function to prevent and/or ameliorate skin-related conditions, thereby transforming the microbiome and/or health of the patient. In another example, the technology can transform biological samples (e.g., through fragmentation, multiplex amplification, sequencing, etc.) received by patients into microbiome datasets, which can subsequently be transformed into features correlated with skin-related conditions, in order to generate characterization models and/or therapy models. In another example, the technology can control therapy systems to promote therapies (e.g., by generating control instructions for the therapy system to execute), thereby transforming the therapy system. In another example, the improvements in computer-related technology can drive transformations in the biological sample processing approaches, such as selecting a subset of primers compatible with genetic targets identified to correspond to microbiome composition features and/or microbiome functional diversity features correlated (e.g., determined based on skin-related feature selection rules) with skin-related conditions.
[0026] Fourth, the technology can amount to an inventive distribution of functionality across a network including a sample handling network, microbiome characterization system, and a plurality of users, where the sample handling network can handle simultaneous processing of biological samples (e.g., in a multiplex manner) from the plurality of users, which can be leveraged by the microbiome characterization system in generating user-personalized characterizations and/or therapies (e.g., customized to the user's microbiome, medical history, demographics, behaviors, preferences, etc.) for skin-related conditions.
[0027] Fifth, the technology can improve the technical fields of at least computational modeling of skin-related conditions in relation to microbiome digital medicine, digital medicine, genetic sequencing, and/or other relevant fields. Sixth, the technology can leverage specialized computing devices (e.g., devices associated with the sample handling network, such as sequencing systems; microbiome characterization systems;
treatment systems; etc.) in determining and processing microbiome datasets for characterizing and/or determining therapies for skin-related conditions. The technology can, however, provide any other suitable benefit(s) in the context of using non-generalized computer systems for microbiome characterization and/or modulation.
3. System.
treatment systems; etc.) in determining and processing microbiome datasets for characterizing and/or determining therapies for skin-related conditions. The technology can, however, provide any other suitable benefit(s) in the context of using non-generalized computer systems for microbiome characterization and/or modulation.
3. System.
[0028] The handling network 210 of the system 200 can function to receive and process (e.g., fragment, amplify, sequence, etc.) biological samples. The handling network 210 can additionally or alternatively function to provide and/or collect sample kits 250 (e.g., including sample containers, instructions for collecting samples, etc.) for a plurality of users (e.g., in response to a purchase order for a sample kit 250), such as through a mail delivery system. In examples, the sample kits 250 can include materials and associated instructions for a user to collect a skin sample (e.g., through cotton tip swabs; aspiration of skin-related fluids such as fluids from a skin lesion; biopsy; etc.). The handling network 210 can additionally or alternatively include a library preparation system operable to automatically prepare biological samples (e.g., fragment and amplify using primers compatible with genetic targets associated with the skin-related condition) in a multiplex manner to be sequenced by a sequencing system; and/or any suitable components. However, the handling network 210 and associated components can be configured in any suitable manner.
[0029] The microbiome characterization system 220 of the system 200 can function to determine and analyze microbiome datasets and/or supplementary datasets for characterizing and/or determining therapies for skin-related conditions. In a variation, the microbiome characterization system 220 can obtain and/or apply computer-implemented rules (e.g., skin-related feature selection rules; model generation rules;
user preference rules; microorganism sequence generation rules; sequence alignment rules; and/or any other suitable rules). However, the microbiome characterization system 220 can be configured in any suitable manner.
user preference rules; microorganism sequence generation rules; sequence alignment rules; and/or any other suitable rules). However, the microbiome characterization system 220 can be configured in any suitable manner.
[0030] The therapy system 230 of the system 200 functions to promote one or more therapies to a user (e.g., subject; care provider administering the therapy;
etc.) for treating a skin-related condition (e.g., reducing the risk of a skin-related infection, etc.).
The therapy system 230 can include any one or more of: a communications system (e.g., to communicate therapy recommendations; to enable telemedicine; etc.; etc.), an application executable on a user device (e.g., a skin-related condition application for promoting proper skincare therapies operable to modify microbiome composition and/or functional diversity in relation to skin-related conditions, etc.), skin-related therapies (e.g., treatments), supplementary medical devices (e.g., medication dispensers; skin treatment applicators; skin grafting devices; radiofrequency-based skin-related devices; hair-related condition devices such as hair restoration devices, hair removal devices; acne-related medical devices; other diagnostic devices such as cutaneous hydration measurement devices; other treatment devices; etc.), user devices (e.g., including biometric sensors), and/or any other suitable component.
etc.) for treating a skin-related condition (e.g., reducing the risk of a skin-related infection, etc.).
The therapy system 230 can include any one or more of: a communications system (e.g., to communicate therapy recommendations; to enable telemedicine; etc.; etc.), an application executable on a user device (e.g., a skin-related condition application for promoting proper skincare therapies operable to modify microbiome composition and/or functional diversity in relation to skin-related conditions, etc.), skin-related therapies (e.g., treatments), supplementary medical devices (e.g., medication dispensers; skin treatment applicators; skin grafting devices; radiofrequency-based skin-related devices; hair-related condition devices such as hair restoration devices, hair removal devices; acne-related medical devices; other diagnostic devices such as cutaneous hydration measurement devices; other treatment devices; etc.), user devices (e.g., including biometric sensors), and/or any other suitable component.
[0031] One or more therapy systems 230 are preferably controllable by the microbiome characterization system 220. For example, the microbiome characterization system 220 can generate control instructions and/or notifications to transmit to the therapy system 230 for activating and/or otherwise operating the therapy system 230 in promoting the therapy. However, the therapy system 230 can be configured in any other manner.
[0032] As shown in FIGURE 9, the system 200 can additionally or alternatively include an interface 240 that can function to improve presentation of skin-related condition information (e.g., characterizations; therapy recommendations; comparisons to other users; evaluations of therapies on microbiome composition and functional diversity;
etc.). In an example, the interface 240 can present skin-related condition information including a microbiome composition (e.g., taxonomic groups), functional diversity (e.g., relative abundance of genes associated with function correlated with skin-related conditions, as shown in FIGURE ii, etc.), and/or risk of infection (e.g., of different skin-related conditions) for the user, such as relative to a user group sharing a demographic characteristic (e.g., patients sharing conditions, smokers, exercisers, users on different dietary regimens, consumers of probiotics, antibiotic users, groups undergoing particular therapies, etc.). In another example, the interface 240 can be operable to present skin-related condition information including a change in the microbiome composition over time and a change in a microbiome functional diversity over time in relation to the treatment and the skin-related condition. In a specific example, the interface's display of skin-related condition information can be improved through selection (e.g., based on components of the characterization satisfying a threshold condition, such as a skin-related condition risk exceeding a threshold, etc.) and presentation of a subset of skin-related condition information (e.g., highlighting and/or otherwise emphasizing a subset of skin-related condition information).
However, the interface 240 can display any suitable information and can be configured in any suitable manner.
etc.). In an example, the interface 240 can present skin-related condition information including a microbiome composition (e.g., taxonomic groups), functional diversity (e.g., relative abundance of genes associated with function correlated with skin-related conditions, as shown in FIGURE ii, etc.), and/or risk of infection (e.g., of different skin-related conditions) for the user, such as relative to a user group sharing a demographic characteristic (e.g., patients sharing conditions, smokers, exercisers, users on different dietary regimens, consumers of probiotics, antibiotic users, groups undergoing particular therapies, etc.). In another example, the interface 240 can be operable to present skin-related condition information including a change in the microbiome composition over time and a change in a microbiome functional diversity over time in relation to the treatment and the skin-related condition. In a specific example, the interface's display of skin-related condition information can be improved through selection (e.g., based on components of the characterization satisfying a threshold condition, such as a skin-related condition risk exceeding a threshold, etc.) and presentation of a subset of skin-related condition information (e.g., highlighting and/or otherwise emphasizing a subset of skin-related condition information).
However, the interface 240 can display any suitable information and can be configured in any suitable manner.
[0033] The system 200 and/or components of the system 200 can entirely or partially be executed by, hosted on, communicate with, and/or otherwise include: a remote computing system (e.g., a server, at least one networked computing system, stateless, stateful), a local computing system, databases (e.g., user database, microbiome dataset database, skin-related condition database, therapy database, etc.), a user device (e.g., a user smart phone, computer, laptop, supplementary medical device, wearable medical device, care provider device, etc.), and/or any suitable component. While the components of the system 200 are generally described as distinct components, they can be physically and/or logically integrated in any manner. For example, a smartphone application can partially or fully implement the microbiome characterization system 220 (e.g., apply a characterization model to generate a characterization of skin-related conditions in real-time; sequence biological samples; process microorganism sequences;
extract features from microbiome datasets; etc.) and the therapy system 230 (e.g., schedule daily events at a calendar application of the smartphone to notify the user to take probiotic therapies in response to generating the characterization).
However, the functionality of the system 200 can be distributed in any suitable manner amongst any suitable system components. Additionally or alternatively, the system 200 and/or method 100 can include any suitable components and/or functions analogous to (e.g., applied in the context of skin-related conditions) those described in U.S.
App. No.
15/452,529 filed 07-MAR-2017, U.S. App. No. 15/374,890 filed 09-DEC-2016, U.S.
App.
No. 14/593,424 filed 09-JAN-2015, U.S. App. No. 15/198,818 filed 30-JUN-2016, U.S.
App. No. 15/098,027 filed 13-APR-2016, U.S. App. No. 15/098,248 filed 13-APR-2016, U.S. App. No. 15/098,236 filed 13-APR-2016, 15/098,222 filed 13-APR-2016, U.S.
App.
No. 15/098,204 filed 13-APR-2016, U.S. App. No. 15/098,174 filed 13-APR-2016, U.S.
App. No. 15/098,110 filed 13-APR-2016, U.S. App. No. 15/098,081 filed 13-APR-2016, U.S. App. No. 15/098,153 filed 13-APR, 2016, U.S. App. No. 15/228,890 filed 04-AUG-2016, and U.S. App. No. 15/240,919 filed 18-AUG-2016, which are each hereby incorporated in their entirety by this reference. However, the components of the system 200 can be configured in any suitable manner.
4. Method.
extract features from microbiome datasets; etc.) and the therapy system 230 (e.g., schedule daily events at a calendar application of the smartphone to notify the user to take probiotic therapies in response to generating the characterization).
However, the functionality of the system 200 can be distributed in any suitable manner amongst any suitable system components. Additionally or alternatively, the system 200 and/or method 100 can include any suitable components and/or functions analogous to (e.g., applied in the context of skin-related conditions) those described in U.S.
App. No.
15/452,529 filed 07-MAR-2017, U.S. App. No. 15/374,890 filed 09-DEC-2016, U.S.
App.
No. 14/593,424 filed 09-JAN-2015, U.S. App. No. 15/198,818 filed 30-JUN-2016, U.S.
App. No. 15/098,027 filed 13-APR-2016, U.S. App. No. 15/098,248 filed 13-APR-2016, U.S. App. No. 15/098,236 filed 13-APR-2016, 15/098,222 filed 13-APR-2016, U.S.
App.
No. 15/098,204 filed 13-APR-2016, U.S. App. No. 15/098,174 filed 13-APR-2016, U.S.
App. No. 15/098,110 filed 13-APR-2016, U.S. App. No. 15/098,081 filed 13-APR-2016, U.S. App. No. 15/098,153 filed 13-APR, 2016, U.S. App. No. 15/228,890 filed 04-AUG-2016, and U.S. App. No. 15/240,919 filed 18-AUG-2016, which are each hereby incorporated in their entirety by this reference. However, the components of the system 200 can be configured in any suitable manner.
4. Method.
[0034]As shown in FIGURES 1A-1B and 2, embodiments of a method 100 for characterizing a skin-related condition in relation to a user can include one or more of:
generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset based on microorganism sequences derived from biological samples (e.g., microorganism genetic sequences derived from the samples) from a set of users Silo; processing a supplementary dataset informative of the skin-related condition for the set of users S120; and performing a characterization process for one or more skin-related conditions, the characterization process derived from the supplementary dataset and features extracted from at least one of the microbiome composition dataset and microbiome functional diversity dataset S130. The method 100 can additionally or alternatively include one or more of: determining a therapy for preventing, ameliorating, and/or otherwise modifying a skin-related condition S140;
processing a biological sample from a user (e.g., subject) Si50; determining, with the characterization process, a characterization of the user based upon processing a microbiome dataset (e.g., microbiome composition dataset, microbiome functional diversity dataset, etc.) derived from the biological sample of the user Si60;
promoting a therapy for the skin-related condition to the user (e.g., based upon the characterization) S170; monitoring effectiveness of the therapy for the user, based upon processing biological samples, to assess microbiome composition and/or functional features associated with the therapy for the user over time Si80; and/or any other suitable operations.
4.1 Method ¨ Processing Datasets.
generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset based on microorganism sequences derived from biological samples (e.g., microorganism genetic sequences derived from the samples) from a set of users Silo; processing a supplementary dataset informative of the skin-related condition for the set of users S120; and performing a characterization process for one or more skin-related conditions, the characterization process derived from the supplementary dataset and features extracted from at least one of the microbiome composition dataset and microbiome functional diversity dataset S130. The method 100 can additionally or alternatively include one or more of: determining a therapy for preventing, ameliorating, and/or otherwise modifying a skin-related condition S140;
processing a biological sample from a user (e.g., subject) Si50; determining, with the characterization process, a characterization of the user based upon processing a microbiome dataset (e.g., microbiome composition dataset, microbiome functional diversity dataset, etc.) derived from the biological sample of the user Si60;
promoting a therapy for the skin-related condition to the user (e.g., based upon the characterization) S170; monitoring effectiveness of the therapy for the user, based upon processing biological samples, to assess microbiome composition and/or functional features associated with the therapy for the user over time Si80; and/or any other suitable operations.
4.1 Method ¨ Processing Datasets.
[0035] Block Silo recites: generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset based on microorganism sequences derived from biological samples from a set of users. Block Silo functions to process each of an aggregate set of biological samples, in order to determine compositional and/or functional aspects associated with the microbiome of each of a population of users. As shown in FIGURE 10, compositional and functional aspects can include compositional aspects at the microorganism level, including parameters related to distribution of microorganisms across different groups of kingdoms, phyla, classes, orders, families, genera, species, subspecies, strains, and/or any other suitable infraspecies taxon (e.g., as measured in total abundance of each group, relative abundance of each group, total number of groups represented, etc.). Compositional and functional aspects can also be represented in terms of operational taxonomic units (OTUs). Compositional and functional aspects can additionally or alternatively include compositional aspects at the genetic level (e.g., regions determined by multilocus sequence typing, 165 sequences, 185 sequences, ITS sequences, other genetic markers, other phylogenetic markers, etc.).
Compositional and functional aspects can include the presence or absence or the quantity of genes associated with specific functions (e.g. enzyme activities, transport functions, immune activities, etc.). Outputs of Block Sno can thus be used to provide features of interest for the characterization process of Block Si3o and/or therapy process of Block Si4o, where the features can be microorganism-based (e.g., presence of a genus of bacteria), genetic-based (e.g., based upon representation of specific genetic regions and/or sequences) and/or functional-based (e.g., presence of a specific catalytic activity), and/or otherwise configured.
Compositional and functional aspects can include the presence or absence or the quantity of genes associated with specific functions (e.g. enzyme activities, transport functions, immune activities, etc.). Outputs of Block Sno can thus be used to provide features of interest for the characterization process of Block Si3o and/or therapy process of Block Si4o, where the features can be microorganism-based (e.g., presence of a genus of bacteria), genetic-based (e.g., based upon representation of specific genetic regions and/or sequences) and/or functional-based (e.g., presence of a specific catalytic activity), and/or otherwise configured.
[0036] In variations of Block Sno, sample processing in Block Sno can include any one or more of: lysing a biological sample, disrupting membranes in cells of a biological sample, separation of undesired elements (e.g., RNA, proteins) from the biological sample, purification of nucleic acids (e.g., DNA) in a biological sample, amplification (e.g., with a library preparation system) of nucleic acids from the biological sample, further purification of amplified nucleic acids of the biological sample, and sequencing of amplified nucleic acids of the biological sample, and/or any other suitable sample processing operations, such as those described in relation to U.S. App. No.
15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
[0037] In variations of Block Silo amplification of purified nucleic acids preferably includes one or more of: polymerase chain reaction (PCR)-based techniques (e.g., solid-phase PCR, RT-PCR, qPCR, multiplex PCR, touchdown PCR, nanoPCR, nested PCR, hot start PCR, etc.), helicase-dependent amplification (HDA), loop mediated isothermal amplification (LAMP), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), strand displacement amplification (SDA), rolling circle amplification (RCA), ligase chain reaction (LCR), and any other suitable amplification technique. In amplification of purified nucleic acids, the primers used are preferably selected to prevent or minimize amplification bias, as well as configured to amplify nucleic acid regions/sequences (e.g., of the 16S region, the 18S region, the ITS region, etc.) that are informative taxonomically, phylogenetically, for diagnostics, for formulations (e.g., for probiotic formulations), and/or for any other suitable purpose.
Thus, universal primers (e.g., a F27-R338 primer set for 16S RNA, a F515-R8o6 primer set for 16S RNA, etc.) configured to avoid amplification bias can be used in amplification. Primers used in variations of Block Silo can additionally or alternatively include incorporated barcode sequences specific to each biological sample, which can facilitate identification of biological samples post-amplification. Selected primers can additionally or alternatively be associated with a skin-related condition and/or microbiome composition features (e.g., identified primers compatible with a genetic target corresponding to microbiome composition features associated with a group of taxa correlated with eczema, etc.), functional diversity features, supplementary features, and/or other features associated with the skin-related conditions. For example, the primers can be complementary to genetic targets associated with the features (e.g., genetic sequences from which relative abundance features are derived; genes associated with different skin-related conditions; etc.). Primers used in variations of Block Sno can additionally or alternatively include adaptor regions configured to cooperate with sequencing techniques involving complementary adaptors (e.g., Illumina Sequencing).
Additionally or alternatively, Block Sno can implement any other step configured to facilitate processing (e.g., using a Nextera kit).
Thus, universal primers (e.g., a F27-R338 primer set for 16S RNA, a F515-R8o6 primer set for 16S RNA, etc.) configured to avoid amplification bias can be used in amplification. Primers used in variations of Block Silo can additionally or alternatively include incorporated barcode sequences specific to each biological sample, which can facilitate identification of biological samples post-amplification. Selected primers can additionally or alternatively be associated with a skin-related condition and/or microbiome composition features (e.g., identified primers compatible with a genetic target corresponding to microbiome composition features associated with a group of taxa correlated with eczema, etc.), functional diversity features, supplementary features, and/or other features associated with the skin-related conditions. For example, the primers can be complementary to genetic targets associated with the features (e.g., genetic sequences from which relative abundance features are derived; genes associated with different skin-related conditions; etc.). Primers used in variations of Block Sno can additionally or alternatively include adaptor regions configured to cooperate with sequencing techniques involving complementary adaptors (e.g., Illumina Sequencing).
Additionally or alternatively, Block Sno can implement any other step configured to facilitate processing (e.g., using a Nextera kit).
[0038] In variations of Block Sno, sequencing of purified nucleic acids can include methods involving targeted amplicon sequencing and/or metagenomic sequencing, implementing techniques including one or more of: sequencing-by-synthesis techniques (e.g., Illumina sequencing), capillary sequencing techniques (e.g., Sanger sequencing), pyrosequencing techniques, and nanopore sequencing techniques (e.g., using an Oxford Nanopore technique).
[0039] In a specific example of Block Sno, amplification and sequencing of nucleic acids from biological samples of the set of biological samples includes: solid-phase PCR
involving bridge amplification of DNA fragments of the biological samples on a substrate with oligo adapters, where amplification involves primers having a forward index sequence (e.g., corresponding to an Illumina forward index for MiSeq/NextSeq/HiSeq platforms), a forward barcode sequence, a transposase sequence (e.g., corresponding to a transposase binding site for MiSeq/NextSeq/HiSeq platforms), a linker (e.g., a zero, one, or two-base fragment configured to reduce homogeneity and improve sequence results), an additional random base, a sequence for targeting a specific target region (e.g., 165 region, 185 region, ITS region), a reverse index sequence (e.g., corresponding to an Illumina reverse index for MiSeq/HiSeq platforms), and a reverse barcode sequence. In the specific example, sequencing includes Illumina sequencing (e.g., with a HiSeq platform, with a MiSeq platform, with a NextSeq platform, etc.) using a sequencing-by-synthesis technique.
involving bridge amplification of DNA fragments of the biological samples on a substrate with oligo adapters, where amplification involves primers having a forward index sequence (e.g., corresponding to an Illumina forward index for MiSeq/NextSeq/HiSeq platforms), a forward barcode sequence, a transposase sequence (e.g., corresponding to a transposase binding site for MiSeq/NextSeq/HiSeq platforms), a linker (e.g., a zero, one, or two-base fragment configured to reduce homogeneity and improve sequence results), an additional random base, a sequence for targeting a specific target region (e.g., 165 region, 185 region, ITS region), a reverse index sequence (e.g., corresponding to an Illumina reverse index for MiSeq/HiSeq platforms), and a reverse barcode sequence. In the specific example, sequencing includes Illumina sequencing (e.g., with a HiSeq platform, with a MiSeq platform, with a NextSeq platform, etc.) using a sequencing-by-synthesis technique.
[0040] Some variations of sample processing in Block Sno can include further purification of amplified nucleic acids (e.g., PCR products) prior to sequencing, which functions to remove excess amplification elements (e.g., primers, dNTPs, enzymes, salts, etc.). In examples, additional purification can be facilitated using any one or more of:
purification kits, buffers, alcohols, pH indicators, chaotropic salts, nucleic acid binding filters, centrifugation, and any other suitable purification technique.
purification kits, buffers, alcohols, pH indicators, chaotropic salts, nucleic acid binding filters, centrifugation, and any other suitable purification technique.
[0041] In variations, computational processing in Block Silo can include any one or more of: identification of microbiome-derived sequences (e.g., as opposed to subject sequences and contaminants), alignment and mapping of microbiome-derived sequences (e.g., alignment of fragmented sequences using one or more of single-ended alignment, ungapped alignment, gapped alignment, pairing), and generating features derived from compositional and/or functional aspects of the microbiome associated with a biological sample.
[0042] In Block Silo, identification of microbiome-derived sequences can include mapping of sequence data from sample processing to a subject reference genome (e.g., provided by the Genome Reference Consortium), in order to remove subject genome-derived sequences. In an example, Block Silo can include determining alignments between microorganism nucleic acid sequences and reference sequences associated with the skin-related condition (e.g., microbiome biomarkers associated with the skin-related conditions, such as biomarkers indicative of a presence and/or abundance of genetic sequences representative of groups of taxa associated with skin-related conditions;
microbiome markers identified through processing microbiome datasets collected by the method loo; etc.) where generating the microbiome composition dataset and the microbiome functional diversity dataset is based on the alignments. However, mapping sequence data can be performed in any suitable manner, such as analogous to U.S. App.
No. 15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
microbiome markers identified through processing microbiome datasets collected by the method loo; etc.) where generating the microbiome composition dataset and the microbiome functional diversity dataset is based on the alignments. However, mapping sequence data can be performed in any suitable manner, such as analogous to U.S. App.
No. 15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
[0043] In Block Silo, upon identification of represented groups of microorganisms of the microbiome associated with a biological sample, generating features derived from compositional and functional aspects of the microbiome associated with a biological sample can be performed. In one variation, generating features can include generating features based upon multilocus sequence typing (MLST), in order to identify markers useful for characterization in subsequent blocks of the method ioo.
Additionally or alternatively, generated features can include generating features that describe the presence or absence of certain taxonomic groups of microorganisms, and/or ratios between exhibited taxonomic groups of microorganisms. Additionally or alternatively, generating features can include generating features describing one or more of:
quantities of represented taxonomic groups, networks of represented taxonomic groups, correlations in representation of different taxonomic groups, interactions between different taxonomic groups, products produced by different taxonomic groups, interactions between products produced by different taxonomic groups, ratios between dead and alive microorganisms (e.g., for different represented taxonomic groups, based upon analysis of RNAs), phylogenetic distance (e.g., in terms of Kantorovich-Rubinstein distances, Wasserstein distances etc.), any other suitable taxonomic group-related feature(s), any other suitable genetic or functional feature(s).
Additionally or alternatively, generated features can include generating features that describe the presence or absence of certain taxonomic groups of microorganisms, and/or ratios between exhibited taxonomic groups of microorganisms. Additionally or alternatively, generating features can include generating features describing one or more of:
quantities of represented taxonomic groups, networks of represented taxonomic groups, correlations in representation of different taxonomic groups, interactions between different taxonomic groups, products produced by different taxonomic groups, interactions between products produced by different taxonomic groups, ratios between dead and alive microorganisms (e.g., for different represented taxonomic groups, based upon analysis of RNAs), phylogenetic distance (e.g., in terms of Kantorovich-Rubinstein distances, Wasserstein distances etc.), any other suitable taxonomic group-related feature(s), any other suitable genetic or functional feature(s).
[0044] In relation to Block Sno, additionally or alternatively, generating features can include generating features describing relative abundance of different microorganism groups, for instance, using a sparCC approach, using Genome Relative Abundance and Average size (GAAS) approach and/or using a Genome Relative Abundance using Mixture Model theory (GRAMMy) approach that uses sequence-similarity data to perform a maximum likelihood estimation of the relative abundance of one or more groups of microorganisms. Additionally or alternatively, generating features can include generating statistical measures of taxonomic variation, as derived from abundance metrics. Additionally or alternatively, generating features can include generating features derived from relative abundance factors (e.g., in relation to changes in abundance of a taxon, which affects abundance of other taxa). Additionally or alternatively, generating features can include generation of qualitative features describing presence of one or more taxonomic groups, in isolation and/or in combination. Additionally or alternatively, generating features can include generation of features related to genetic markers (e.g., representative 16S, 18S, and/or ITS
sequences) characterizing microorganisms of the microbiome associated with a biological sample.
Additionally or alternatively, generating features can include generation of features related to functional associations of specific genes and/or organisms having the specific genes. Additionally or alternatively, generating features can include generation of features related to pathogenicity of a taxon and/or products attributed to a taxon. Block S120 can, however, include generation of any other suitable feature(s) derived from sequencing and mapping of nucleic acids of a biological sample. For instance, the feature(s) can be combinatory (e.g. involving pairs, triplets), correlative (e.g., related to correlations between different features), and/or related to changes in features (e.g., temporal changes, changes across sample sites, etc., spatial changes, etc.).
However, Block Silo can be performed in any suitable manner.
sequences) characterizing microorganisms of the microbiome associated with a biological sample.
Additionally or alternatively, generating features can include generation of features related to functional associations of specific genes and/or organisms having the specific genes. Additionally or alternatively, generating features can include generation of features related to pathogenicity of a taxon and/or products attributed to a taxon. Block S120 can, however, include generation of any other suitable feature(s) derived from sequencing and mapping of nucleic acids of a biological sample. For instance, the feature(s) can be combinatory (e.g. involving pairs, triplets), correlative (e.g., related to correlations between different features), and/or related to changes in features (e.g., temporal changes, changes across sample sites, etc., spatial changes, etc.).
However, Block Silo can be performed in any suitable manner.
[0045] Block S120 recites: receiving a supplementary dataset, associated with at least a subset of the population of users, where the supplementary dataset facilitates characterization of users. Block S120 functions to acquire additional data associated with one or more users of the set of users, which can be used to train and/or validate the characterization process generated in Block S13o. In Block S120, the supplementary dataset preferably includes survey-derived data, but can additionally or alternatively include any one or more of: contextual data derived from sensors, medical data (e.g., current and historical medical data), and any other suitable type of data. In variations of Block S120 including reception of survey-derived data, the survey-derived data preferably provides physiological, demographic, and behavioral information in association with a user. However, types of supplementary data and manners of collecting supplementary data can be analogous to that described in U.S. App.
No.
15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference, but processing supplementary datasets can be performed in any suitable manner.
4.2 Method - Performing a Characterization Process.
No.
15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference, but processing supplementary datasets can be performed in any suitable manner.
4.2 Method - Performing a Characterization Process.
[0046] Block Si3o recites: performing a characterization process for one or more skin-related conditions, the characterization process derived from the supplementary dataset and features extracted from at least one of the microbiome composition dataset and microbiome functional diversity dataset S13o. Block S13o functions to identify features and/or feature combinations that can be used to characterize users or groups based upon their microbiome composition and/or functional features. As such, the characterization process can be used as a diagnostic tool that can characterize a user (e.g., in terms of behavioral traits, in terms of medical conditions, in terms of demographic traits, etc.) based upon their microbiome composition and/or functional features, in relation to one or more of their health condition states, behavioral traits, medical conditions, demographic traits, and any other suitable traits. Such characterization can then be used to suggest or provide personalized therapies by way of the therapy model of Block S14o.
[0047]In performing the characterization process, Block S13o can use computational methods (e.g., statistical methods, machine learning methods, artificial intelligence methods, bioinformatics methods, etc.) to characterize a user as exhibiting features characteristic of a group of users with a health condition. However, the characterization process can be performed in any suitable manner.
[0048] In variations of Block S13o, performing a characterization process can include generating one or more characterizations of one or more skin-related conditions. In some examples, the characterization process of Block S13o can facilitate identification of which microorganism population(s) (e.g., taxonomic groups, microbiome composition features, etc.) are upregulated or downregulated in relation to skin-related conditions, and/or which microbiome functional aspects (e.g., in relation to Clusters of Orthologous Groups / Kyoto Encyclopedia of Genes and Genomes pathways, microbiome functional diversity features, etc.) are upregulated or downregulated in relation to skin-related conditions. Characterizing upregulation and/or downregulation can be at any suitable taxonomic level (e.g., kingdom, phylum, class, order, family, genus, species, strain, etc.), any suitable granularity of functional diversity, and/or at any suitable granularity.
[0049] In another variation, characterizing a skin-related condition in Block S13o can include generating a diagnostic analysis (e.g., estimating a risk of being inflicted by the skin-related condition; calculating the change in risk conferred by an identified therapy;
diagnosing the presence of the skin-related condition; diagnosing the severity of the skin-related condition over time in relation to microbiome composition and/or functional diversity; etc.) and/or associated complications. In another variation of Block S13o, characterizing a skin-related condition can be based on one or more supplementary datasets. For example, the set of feature-selection rules can correlate one or more skin-related conditions to one or more biometric features derived from biometric sensor data informative of a skin-related condition (e.g., optical data of the skin such as skin lesions, acne, etc.; skin-related parameters, such as cutaneous hydration, associated with skin-related conditions; blood data; temperature data; user behavior data; temperature data; cardiovascular data; stool data; etc.). In another example, performing a characterization process can include determining a series of characterizations over time based on therapies promoted over time (e.g., based on therapy data including antibiotic regimen data, probiotic regimen data, and/or other suitable therapy data collected over time and associated with a population of users), where the effect of different therapies over time can aid in illuminating insights associated with microbiome compositions and/or functional diversity correlated with skin-related conditions. However, performing a characterization process in relation to a skin-related condition can be performed in any suitable manner.
diagnosing the presence of the skin-related condition; diagnosing the severity of the skin-related condition over time in relation to microbiome composition and/or functional diversity; etc.) and/or associated complications. In another variation of Block S13o, characterizing a skin-related condition can be based on one or more supplementary datasets. For example, the set of feature-selection rules can correlate one or more skin-related conditions to one or more biometric features derived from biometric sensor data informative of a skin-related condition (e.g., optical data of the skin such as skin lesions, acne, etc.; skin-related parameters, such as cutaneous hydration, associated with skin-related conditions; blood data; temperature data; user behavior data; temperature data; cardiovascular data; stool data; etc.). In another example, performing a characterization process can include determining a series of characterizations over time based on therapies promoted over time (e.g., based on therapy data including antibiotic regimen data, probiotic regimen data, and/or other suitable therapy data collected over time and associated with a population of users), where the effect of different therapies over time can aid in illuminating insights associated with microbiome compositions and/or functional diversity correlated with skin-related conditions. However, performing a characterization process in relation to a skin-related condition can be performed in any suitable manner.
[0050] Block S13o can additionally or alternatively include Block S132:
generating features, which can function to generate one or more features for the characterization process (e.g., for use in training a characterization model). Features can include any one or more of: microbiome composition features (e.g., absolute and/or relative abundance of taxonomic groups in a user's microbiome), microbiome functional diversity features, and/or other suitable features. Microbiome functional diversity features can include any one or more of: Kyoto Encyclopedia of Genes and Genomes (KEGG) functional features (e.g., KEGG features associated with flagellum biosynthesis, etc.), Clusters of Orthologous Groups (COG) of proteins features, L2, L3, L4 derived features, genomic functional features, functional features associated with and/or specific to a taxonomic group, chemical functional features (e.g., cysteine metabolism, etc.), systemic functional features (e.g., systemic immune function; functions associated with systemic diseases;
etc.), and/or any suitable functional features. Microbiome features can additionally or alternatively be derived from and/or associated with at least one of: relative abundance monotonic transformations, non-monotonic transformations, normalizations, feature vectors such as derived from at least one of linear latent variable analysis and nonlinear latent variable analysis, linear regression, nonlinear regression, kernel methods, feature embedding methods, machine learning, statistical inference methods and/or any other suitable approaches.
generating features, which can function to generate one or more features for the characterization process (e.g., for use in training a characterization model). Features can include any one or more of: microbiome composition features (e.g., absolute and/or relative abundance of taxonomic groups in a user's microbiome), microbiome functional diversity features, and/or other suitable features. Microbiome functional diversity features can include any one or more of: Kyoto Encyclopedia of Genes and Genomes (KEGG) functional features (e.g., KEGG features associated with flagellum biosynthesis, etc.), Clusters of Orthologous Groups (COG) of proteins features, L2, L3, L4 derived features, genomic functional features, functional features associated with and/or specific to a taxonomic group, chemical functional features (e.g., cysteine metabolism, etc.), systemic functional features (e.g., systemic immune function; functions associated with systemic diseases;
etc.), and/or any suitable functional features. Microbiome features can additionally or alternatively be derived from and/or associated with at least one of: relative abundance monotonic transformations, non-monotonic transformations, normalizations, feature vectors such as derived from at least one of linear latent variable analysis and nonlinear latent variable analysis, linear regression, nonlinear regression, kernel methods, feature embedding methods, machine learning, statistical inference methods and/or any other suitable approaches.
[0051] Regarding Block S132, determining features is preferably based on processing microbiome composition data and/or microbiome functional diversity data according to one or more computer-implemented rules (e.g., a feature-selection rule, a user preference rule, etc.), but features can be determined based on any suitable information.
For example, the method loo can include obtaining a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and/or a subset of microbiome functional diversity features (e.g., from a pool of potential microbiome composition and/or functional diversity features);
and generating features based on evaluating the microbiome composition data and the microbiome functional diversity data against the set of skin-related feature-selection rules, where the set of skin-related feature selection rules are operable to improve the microbiome characterization system (e.g., by facilitating decreased processing time such as for transforming supplementary data and features into a characterization model; by improving speed of model retrieval, and/or execution; by improving characterization and/or therapy provision accuracy; etc.). Block S132 and/or other portions of the method loo preferably include applying computer-implemented rules to process population-level data, but can additionally or alternatively include applying computer-implemented rules to process microbiome-related data on a demographic-specific basis (e.g., subgroups sharing a demographic feature such as skin hygiene regimens, ethnicity, age, gender, etc.), condition-specific basis (e.g., subgroups exhibiting a particular skin-related condition), a sample type-specific basis (e.g., applying different computer-implemented rules to process microbiome data derived from skin samples versus fecal matter samples), and/or any other suitable basis. As such, Block S132 can include assigning users from the population of users to one or more subgroups; and applying different computer-implemented rules for determining features (e.g., the set of feature types used; the types of characterization models generated from the features;
etc.) for the different subgroups.
For example, the method loo can include obtaining a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and/or a subset of microbiome functional diversity features (e.g., from a pool of potential microbiome composition and/or functional diversity features);
and generating features based on evaluating the microbiome composition data and the microbiome functional diversity data against the set of skin-related feature-selection rules, where the set of skin-related feature selection rules are operable to improve the microbiome characterization system (e.g., by facilitating decreased processing time such as for transforming supplementary data and features into a characterization model; by improving speed of model retrieval, and/or execution; by improving characterization and/or therapy provision accuracy; etc.). Block S132 and/or other portions of the method loo preferably include applying computer-implemented rules to process population-level data, but can additionally or alternatively include applying computer-implemented rules to process microbiome-related data on a demographic-specific basis (e.g., subgroups sharing a demographic feature such as skin hygiene regimens, ethnicity, age, gender, etc.), condition-specific basis (e.g., subgroups exhibiting a particular skin-related condition), a sample type-specific basis (e.g., applying different computer-implemented rules to process microbiome data derived from skin samples versus fecal matter samples), and/or any other suitable basis. As such, Block S132 can include assigning users from the population of users to one or more subgroups; and applying different computer-implemented rules for determining features (e.g., the set of feature types used; the types of characterization models generated from the features;
etc.) for the different subgroups.
[0052]In a variation, Block S132 can include applying feature-selection rules (e.g., feature selection algorithms such as exhaustive, best first, simulated annealing, greedy forward, greedy backward, and/or other suitable feature selection algorithms) to filter, rank, and/or otherwise select features for use in generating one or more characterization models (e.g., using skin-related feature-selection rules correlating one or more skin-related conditions to microbiome composition features and/or microbiome functional diversity features, etc.), therapy models (e.g., using rules correlating one or more therapies to one or more microbiome composition features, microbiome functional diversity features, and/or features derived from characterizations generated in Block Si6o, etc.), and/or other suitable models. As shown in FIGURE 12, in a variation, application of feature-selection rules can lead to microbiome-related insights upon which modifications in sample processing (e.g., parameters such as techniques, experimental conditions, in Blocks S110-S12o, S15o, etc.) can be based. For example, the method 100 can include: applying a set of skin-related feature selection rules to identify features (e.g., microbiome composition features indicating particular taxonomic groups; microbiome functional diversity features indicating particular microorganism functions) correlated (e.g., most correlated; etc.) with the skin-related conditions (e.g., presence, risk, therapies, etc.);
and selecting primers (e.g., for use in amplification and sequencing to generate microbiome datasets; etc.) compatible with genetic targets associated with the identified features (e.g., using primers associated with genetic targets corresponding to the microbiome functional diversity features correlated with the skin-related condition;
etc.). As such, the feature-selection rules and/or other computer-implemented rules can additionally or alternatively function to determine sample processing parameters (e.g., described in relation to Blocks S110-S12o, S15o, etc.). Additionally or alternatively, applying feature-selection rules can be performed in a manner analogous to U.S. App.
No. 15/452,529 filed 07-MAR-2017, which is herein incorporated in its entirety by this reference, and/or can be performed in any suitable manner. However, any suitable number and/or type of feature-selection rules can be applied in any manner to define one or more feature sets.
and selecting primers (e.g., for use in amplification and sequencing to generate microbiome datasets; etc.) compatible with genetic targets associated with the identified features (e.g., using primers associated with genetic targets corresponding to the microbiome functional diversity features correlated with the skin-related condition;
etc.). As such, the feature-selection rules and/or other computer-implemented rules can additionally or alternatively function to determine sample processing parameters (e.g., described in relation to Blocks S110-S12o, S15o, etc.). Additionally or alternatively, applying feature-selection rules can be performed in a manner analogous to U.S. App.
No. 15/452,529 filed 07-MAR-2017, which is herein incorporated in its entirety by this reference, and/or can be performed in any suitable manner. However, any suitable number and/or type of feature-selection rules can be applied in any manner to define one or more feature sets.
[0053] In an example, in Block S132, feature-selection rules can include application of a statistical analysis (e.g., an analysis of probability distributions) of similarities and/or differences between a first group of users exhibiting a target state (e.g., a health condition state) and a second group of users not exhibiting the target state (e.g., a "normal" state). In implementing this variation, one or more of a Kolmogorov-Smirnov (KS) test, a permutation test, a Cramer-von Mises test, and any other statistical test (e.g., t-test, z-test, chi-squared test, test associated with distributions, etc.) can be used.
In particular, one or more such statistical hypothesis tests can be used to assess a set of features having varying degrees of abundance in a first group of users exhibiting a target state (e.g., a sick state) and a second group of users not exhibiting the target state (e.g., having a normal state). In more detail, the set of features assessed can be constrained based upon percent abundance and/or any other suitable parameter pertaining to diversity in association with the first group of users and the second group of users, in order to increase or decrease confidence in the characterization. In a specific implementation of this example, a feature can be derived from a taxon of bacteria that is abundant in a certain percentage of users of the first group and users of the second group, where a relative abundance of the taxon between the first group of users and the second group of users can be determined from the KS test, with an indication of significance (e.g., in terms of p-value). Thus, an output of Block S132 can include a normalized relative abundance value (e.g., 25% greater abundance of a taxon in sick users vs. healthy users) with an indication of significance (e.g., a p-value of 0.0013).
Variations of feature generation can additionally or alternatively implement or be derived from functional features or metadata features (e.g., non-bacterial markers)
In particular, one or more such statistical hypothesis tests can be used to assess a set of features having varying degrees of abundance in a first group of users exhibiting a target state (e.g., a sick state) and a second group of users not exhibiting the target state (e.g., having a normal state). In more detail, the set of features assessed can be constrained based upon percent abundance and/or any other suitable parameter pertaining to diversity in association with the first group of users and the second group of users, in order to increase or decrease confidence in the characterization. In a specific implementation of this example, a feature can be derived from a taxon of bacteria that is abundant in a certain percentage of users of the first group and users of the second group, where a relative abundance of the taxon between the first group of users and the second group of users can be determined from the KS test, with an indication of significance (e.g., in terms of p-value). Thus, an output of Block S132 can include a normalized relative abundance value (e.g., 25% greater abundance of a taxon in sick users vs. healthy users) with an indication of significance (e.g., a p-value of 0.0013).
Variations of feature generation can additionally or alternatively implement or be derived from functional features or metadata features (e.g., non-bacterial markers)
[0054] In another variation, Block S132 can additionally or alternatively transform input data from at least one of the microbiome composition diversity dataset and microbiome functional diversity dataset into feature vectors that can be tested for efficacy in predicting characterizations of the population of users. Data from the supplementary dataset can be used to provide indication of one or more characterizations of a set of characterizations, where the characterization process is trained with a training dataset of candidate features and candidate classifications to identify features and/or feature combinations that have high degrees (or low degrees) of predictive power in accurately predicting a classification. As such, refinement of the characterization process with the training dataset identifies feature sets (e.g., of user features, of combinations of features) having high correlation with specific classifications of users.
[0055] In variations of Block S132, feature vectors effective in predicting classifications of the characterization process can include features related to one or more of:
microbiome diversity metrics (e.g., in relation to distribution across taxonomic groups, in relation to distribution across archaeal, bacterial, viral, and/or eukaryotic groups), presence of taxonomic groups in one's microbiome, representation of specific genetic sequences (e.g., 16S sequences) in one's microbiome, relative abundance of taxonomic groups in one's microbiome, microbiome resilience metrics (e.g., in response to a perturbation determined from the supplementary dataset), abundance of genes that encode proteins or RNAs with given functions (enzymes, transporters, proteins from the immune system, hormones, interference RNAs, etc.) and/or any other suitable features derived from the microbiome diversity dataset and/or the supplementary dataset. For example, Block S132 can include generating a set of microbiome feature vectors (e.g., a feature vector for each user of subgroup or population of users) based on microbiome composition features (e.g., a subset selected based on feature-selection rules), microbiome functional diversity features (e.g., a subset selected based on feature-selection rules), and supplementary features (e.g., biometric features derived from the supplementary biometric sensor data, etc.), where the set of microbiome feature vectors can be used in training the characterizations model and/or other suitable models.
Additionally or alternatively, combinations of features can be used in a feature vector, where features can be grouped and/or weighted in providing a combined feature as part of a feature set. For example, one feature or feature set can include a weighted composite of the number of represented classes of bacteria in one's microbiome, presence of a specific genus of bacteria in one's microbiome, representation of a specific 16S sequence in one's microbiome, and relative abundance of a first phylum over a second phylum of bacteria. However, the feature vectors and features can additionally or alternatively be determined in any other suitable manner.
microbiome diversity metrics (e.g., in relation to distribution across taxonomic groups, in relation to distribution across archaeal, bacterial, viral, and/or eukaryotic groups), presence of taxonomic groups in one's microbiome, representation of specific genetic sequences (e.g., 16S sequences) in one's microbiome, relative abundance of taxonomic groups in one's microbiome, microbiome resilience metrics (e.g., in response to a perturbation determined from the supplementary dataset), abundance of genes that encode proteins or RNAs with given functions (enzymes, transporters, proteins from the immune system, hormones, interference RNAs, etc.) and/or any other suitable features derived from the microbiome diversity dataset and/or the supplementary dataset. For example, Block S132 can include generating a set of microbiome feature vectors (e.g., a feature vector for each user of subgroup or population of users) based on microbiome composition features (e.g., a subset selected based on feature-selection rules), microbiome functional diversity features (e.g., a subset selected based on feature-selection rules), and supplementary features (e.g., biometric features derived from the supplementary biometric sensor data, etc.), where the set of microbiome feature vectors can be used in training the characterizations model and/or other suitable models.
Additionally or alternatively, combinations of features can be used in a feature vector, where features can be grouped and/or weighted in providing a combined feature as part of a feature set. For example, one feature or feature set can include a weighted composite of the number of represented classes of bacteria in one's microbiome, presence of a specific genus of bacteria in one's microbiome, representation of a specific 16S sequence in one's microbiome, and relative abundance of a first phylum over a second phylum of bacteria. However, the feature vectors and features can additionally or alternatively be determined in any other suitable manner.
[0056] Block S13o can additionally or alternatively include Block S134:
generating a characterization model. Block S134 functions to generate one or more characterization models for skin-related conditions based on applying one or more features, microbiome datasets, supplementary data, and/or any other suitable data. Characterization models (and/or therapy models or other suitable models) can include any one or more of:
probabilistic properties, heuristic properties, deterministic properties, and/or any other suitable properties. Block S134 and/or any other suitable portions of the method 100 (e.g., generating a therapy model S14o) can employ one or more algorithms analogous to those described in U.S. App. No. 15/452,529 filed 07-MAR-2017 and/or U.S.
App. No.
15/374,890 filed 09-DEC-2016, which are incorporated in their entirety by this reference, but any suitable algorithms can be employed.
generating a characterization model. Block S134 functions to generate one or more characterization models for skin-related conditions based on applying one or more features, microbiome datasets, supplementary data, and/or any other suitable data. Characterization models (and/or therapy models or other suitable models) can include any one or more of:
probabilistic properties, heuristic properties, deterministic properties, and/or any other suitable properties. Block S134 and/or any other suitable portions of the method 100 (e.g., generating a therapy model S14o) can employ one or more algorithms analogous to those described in U.S. App. No. 15/452,529 filed 07-MAR-2017 and/or U.S.
App. No.
15/374,890 filed 09-DEC-2016, which are incorporated in their entirety by this reference, but any suitable algorithms can be employed.
[0057] In an example of Block S134, a characterization model can be generated and trained according to a random forest predictor (RFP) algorithm that combines bagging (e.g., bootstrap aggregation) and selection of random sets of features from a training dataset to construct a set of decision trees, T, associated with the random sets of features. In using a random forest algorithm, N cases from the set of decision trees are sampled at random with replacement to create a subset of decision trees, and for each node, m prediction features are selected from all of the prediction features for assessment. The prediction feature that provides the best split at the node (e.g., according to an objective function) is used to perform the split (e.g., as a bifurcation at the node, as a trifurcation at the node). By sampling many times from a large dataset, the strength of the characterization process, in identifying features that are strong in predicting classifications can be increased substantially. In this variation, measures to prevent bias (e.g., sampling bias) and/or account for an amount of bias can be included during processing to increase robustness of the model. In another example, characterization of the user(s) can additionally or alternatively implement use of a high false positive test and/or a high false negative test to further analyze sensitivity of the characterization process in supporting analyses generated according to embodiments of the method 100. However, preventing bias and/or improving sensitivity can be performed in any suitable manner.
[0058] In another variation of Block S134, different characterization models can be generated for different demographic groups (e.g., a first characterization model characterizing a skin-related condition for users who bathe on a daily basis, a second characterization model for users who bathe on a non-daily basis, etc.), skin-associated conditions (e.g., different characterization models for eczema, dry skin, pimple-related conditions, scalp-related conditions, photosensitivity, dandruff, etc., as shown in FIGURE 5), individual users, supplementary data (e.g., models incorporating features derived from biometric sensor data and/or survey response data vs. models independent of supplementary data, etc.), and/or other suitable criteria. In an example, the method 100 can include generating a first characterization model (e.g., eczema-related characterization model for eczema) based on a first feature set derived from at least one of the microbiome composition dataset and microbiome functional diversity dataset; and generating one or more additional characterization models (e.g., scalp-related characterization model for scalp-related conditions; dry-skin related characterization model for dry skin-related conditions; etc.) based on additional feature sets (e.g., sharing feature types with the first feature set or other feature sets; including a set of feature types distinct from those of the first feature set or other feature sets; etc.) derived from the at least one of the microbiome composition dataset and the microbiome functional diversity dataset, and/or other suitable data (e.g., other microbiome composition datasets and/or functional diversity datasets, etc.).
As shown in FIGURE 5, characterizations outputted from different characterization models can be used in determining and/or promoting a therapy, such as by inputting features derived from a different characterizations (e.g., outputs by an eczema-related characterization model, a scalp-related characterization model, dry skin-related characterization model, etc.) into a therapy model (e.g., to generate a single therapy or a plurality of therapies tailored to treating the different skin-related conditions, etc.).
As shown in FIGURE 5, characterizations outputted from different characterization models can be used in determining and/or promoting a therapy, such as by inputting features derived from a different characterizations (e.g., outputs by an eczema-related characterization model, a scalp-related characterization model, dry skin-related characterization model, etc.) into a therapy model (e.g., to generate a single therapy or a plurality of therapies tailored to treating the different skin-related conditions, etc.).
[0059] In another example, Block S134 can include generating a characterization model for a demographic group of users sharing a skin hygiene characteristic (e.g., using moisturizer, bathing, sunscreen, at a particular frequency, etc.); associating the characterization model with user accounts (e.g., at a database of the microbiome characterization system) for the users who indicate the skin hygiene characteristic (e.g., at a digital survey presented by the interface; based on user device sensor data such as location data); and retrieving the characterization model (e.g., from the database) for characterizing the users. Generating a plurality of characterization models suited to different contexts can confer improvements to the microbiome characterization system by improving characterization accuracy (e.g., by tailoring analysis to a particular user's demographic and/or situation, etc.), retrieval speed for the appropriate characterization model from a database (e.g., by associating customized characterization models with particular user accounts and/or other identifiers), training and/or execution of characterization models (e.g., where the customized models are associated with a subset of a pool of potential features correlated with skin-related conditions, and where the remaining unselected features are less correlated with the skin-related conditions), and/or other suitable aspects of the microbiome characterization system.
[0060] In another variation of Block S134, generating feature sets for different characterization models (and/or therapy models) can be based on different feature selection rules (e.g., applying eczema-associated feature-selection rules to generate a feature set specific to eczema in generating an eczema-related characterization model, etc.). Alternatively, overlapping or the same set of feature selection rules can be used for generating different characterization models (e.g., using the same functional diversity feature in generating two different characterization models for two different skin-related conditions, etc.). Additionally or alternatively, generating any number of characterization models can be performed in any suitable manner.
[0061] In another variation of Block S134, performing a characterization process can be based upon statistical analyses that identify the sets of features that have the highest correlations with one or more skin-related conditions for which one or more therapies would have a positive effect, based upon a Kolmogorov-Smirnov statistical test that compares a dataset derived from a subset of the population of users that present the skin-related condition, and a dataset derived from a subset of the population of users that do not present the skin-related condition. However, performing characterization processes can be performed in any suitable manner.
4.2.1 Characterization Process ¨ Photosensitivity Characterization
4.2.1 Characterization Process ¨ Photosensitivity Characterization
[0062] In variations of Block S13o, performing a characterization process can be for one or more photosensitivity-associated conditions. In particular, photosensitivity can be a skin condition characterized by an abnormal reaction of the skin to a component of the electromagnetic spectrum of sunlight. It is typically diagnosed by skin examination, phototests and photopatch tests. In addition, photosensitivity-associated conditions can be associated with specific microbiota diversity and/or health conditions related to relative abundance of gut microorganisms, and/or microbiome functional diversity.
[0063] In variations of Block S13o, a set of features useful for characterizations of photosensitivity-associated conditions and/or other skin-associated conditions can include features derived from one or more of the following taxa:
Marvinbryantia (genus), Erysipelotrichales (order), Erysipelotrichia (class), Bacteroidetes (phylum), and/or any other suitable taxa. Thus, characterization of the subject comprises characterization of the subject as someone with photosensitivity based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
Marvinbryantia (genus), Erysipelotrichales (order), Erysipelotrichia (class), Bacteroidetes (phylum), and/or any other suitable taxa. Thus, characterization of the subject comprises characterization of the subject as someone with photosensitivity based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
[0064]Additionally or alternatively, in Block S13o, the set of features can include functional features (e.g., diversity features) associated with photosensitivity-associated conditions (e.g., associated with photosensitivity diagnostics using skin samples) and/or other skin-associated conditions, including one or more of: COG derived features, KEGG
L2, L3, L4 derived features, and any other suitable functional features. In specific examples, such features can include: an infectious diseases KEGG L2 derived feature.
L2, L3, L4 derived features, and any other suitable functional features. In specific examples, such features can include: an infectious diseases KEGG L2 derived feature.
[0065] However, performing the characterization process for photosensitivity-associated conditions can be performed in any suitable manner using any suitable features.
4.2.2 Characterization Process ¨ Dry skin Characterization.
4.2.2 Characterization Process ¨ Dry skin Characterization.
[0066] In variations of Block S13o, performing a characterization process can be for one or more dry skin-associated conditions. In particular, dry skin can be characterized by rough skin, itching, flaking, scaling or peeling, fine lines or cracks, gray skin in people with dark skin, redness, deep cracks that may bleed and which can lead to infections. In addition, dry skin-associated conditions can be associated with specific microbiota diversity and/or health conditions related to relative abundance of gut microorganisms, and/or microbiome functional diversity.
[0067] In variations of the characterization process of Block S13o, a set of features useful for characterizations of dry skin-associated conditions and/or other skin-associated conditions can include features derived from one or more of the following taxa:
Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), Propionibacterium (genus), and/or any other suitable taxa, where sampling of subjects can involve sampling of the skin and/or other body region. Thus, characterization of the subject comprises characterization of the subject as someone with dry skin based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), Propionibacterium (genus), and/or any other suitable taxa, where sampling of subjects can involve sampling of the skin and/or other body region. Thus, characterization of the subject comprises characterization of the subject as someone with dry skin based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
[0068]Additionally or alternatively, in Block S13o, the set of features can include functional diversity features associated with dry skin-associated conditions (e.g., associated with dry skin diagnostics using skin samples) and/or other skin-associated conditions, including one or more of: COG derived features, KEGG L2, L3, L4 derived features and/or any other suitable combination of features. However, performing the characterization process for dry skin-associated conditions can be performed in any suitable manner using any suitable features.
4.2.3 Characterization Process ¨ Dandruff Characterization
4.2.3 Characterization Process ¨ Dandruff Characterization
[0069] In variations of Block S13o, performing a characterization process can be for one or more scalp-related conditions. In particular, dandruff can be a chronic scalp condition characterized by flaking, itching and scaling of the skin in the scalp, that can be caused by dry skin, irritated oily skin, sensitivity to hair care products, that finally results in an imbalance of the scalp microbiome. In addition, scalp-related conditions can be associated with specific microbiota diversity and/or health conditions related to relative abundance of gut microorganisms, and/or microbiome functional diversity.
[0070] In variations of Block S13o, a set of features useful for characterizations of dandruff conditions and/or other scalp-associated conditions can include features derived from one or more of the following taxa: Propionibacterium sp. MSPo9A
(species), Bacteroides vulgatus (species, Streptococcus sp. BS35a (species), Staphylococcus sp. C9I2 (species), Phascolarctobacterium sp. 377 (species), Faecalibacterium prausnitzii (species), Alistipes putredinis (species), Alistipes sp.
EBA6-25c12 (species), Alistipes sp. RMA 9912 (species) Anaerostipes sp. 5 1 (species), Bacteroides acidifaciens (species), Bacteroides caccae (species), Bacteroides fragilis (species), Bacteroides plebeius (species), Bacteroides sp. AR2o (species), Bacteroides sp. AR29 (species), Bacteroides sp. D22 (species), Bacteroides sp.
DJF
(species), Bacteroides sp. SLC1-38 (species), Bacteroides sp. XB12B (species), Bacteroides vulgatus (species), Blautia faecis (species), Blautia luti (species), Blautia sp.
YHC-4 (species), Blautia stercoris (species), Blautia wexlerae (species), Collinsella aerofaciens (species), Corynebacterium sp. (species), Corynebacterium spheniscorum (species), Corynebacterium ulcerans (species), Dorea formicigenerans (species), Dorea longicatena (species), Lachnospira pectinoschiza (species), Odoribacter splanchnicus (species), Parabacteroides distasonis (species), Parabacteroides merdae (species), Phascolarctobacterium faecium (species), Propionibacterium acnes (species), Propionibacterium granulosum (species), Propionibacterium sp. MSPo9A
(species), Roseburia intestinalis (species), Roseburia inulinivorans (species), Roseburia sp.
11SE39 (species), Staphylococcus sp. C9I2 (species), Staphylococcus sp. WB18-(species), Streptococcus sp. BS35a (species), Streptococcus sp. oral taxon G59 (species), Streptococcus thermophilus (species), Subdoligranulum variabile (species), Sutterella stercoricanis (species), Sutterella wadsworthensis Propionibacterium (genus), Staphylococcus (genus), Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Bifidobacterium (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Dialister (genus), Prevotella (genus), Marvinbryantia (genus), Propionibacteriaceae (family), Staphylococcaceae (family), Porphyromonadaceae (family), Lachnospiraceae (family), Peptostreptococcaceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Bifidobacteriaceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Actinomycetales (order), Selenomonadales (order), Bacillales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Bifidobacteriales (order), Pasteurellales (order), Actinobacteria (class), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Bacilli (class), Deltaproteobacteria (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Actinobacteria (phylum), Proteobacteria (phylum), Firmicutes (phylum), Verrucomicrobia (phylum), and/or any other suitable taxa. Thus, characterization of the subject comprises characterization of the subject as someone with dandruff based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
(species), Bacteroides vulgatus (species, Streptococcus sp. BS35a (species), Staphylococcus sp. C9I2 (species), Phascolarctobacterium sp. 377 (species), Faecalibacterium prausnitzii (species), Alistipes putredinis (species), Alistipes sp.
EBA6-25c12 (species), Alistipes sp. RMA 9912 (species) Anaerostipes sp. 5 1 (species), Bacteroides acidifaciens (species), Bacteroides caccae (species), Bacteroides fragilis (species), Bacteroides plebeius (species), Bacteroides sp. AR2o (species), Bacteroides sp. AR29 (species), Bacteroides sp. D22 (species), Bacteroides sp.
DJF
(species), Bacteroides sp. SLC1-38 (species), Bacteroides sp. XB12B (species), Bacteroides vulgatus (species), Blautia faecis (species), Blautia luti (species), Blautia sp.
YHC-4 (species), Blautia stercoris (species), Blautia wexlerae (species), Collinsella aerofaciens (species), Corynebacterium sp. (species), Corynebacterium spheniscorum (species), Corynebacterium ulcerans (species), Dorea formicigenerans (species), Dorea longicatena (species), Lachnospira pectinoschiza (species), Odoribacter splanchnicus (species), Parabacteroides distasonis (species), Parabacteroides merdae (species), Phascolarctobacterium faecium (species), Propionibacterium acnes (species), Propionibacterium granulosum (species), Propionibacterium sp. MSPo9A
(species), Roseburia intestinalis (species), Roseburia inulinivorans (species), Roseburia sp.
11SE39 (species), Staphylococcus sp. C9I2 (species), Staphylococcus sp. WB18-(species), Streptococcus sp. BS35a (species), Streptococcus sp. oral taxon G59 (species), Streptococcus thermophilus (species), Subdoligranulum variabile (species), Sutterella stercoricanis (species), Sutterella wadsworthensis Propionibacterium (genus), Staphylococcus (genus), Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Bifidobacterium (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Dialister (genus), Prevotella (genus), Marvinbryantia (genus), Propionibacteriaceae (family), Staphylococcaceae (family), Porphyromonadaceae (family), Lachnospiraceae (family), Peptostreptococcaceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Bifidobacteriaceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Actinomycetales (order), Selenomonadales (order), Bacillales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Bifidobacteriales (order), Pasteurellales (order), Actinobacteria (class), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Bacilli (class), Deltaproteobacteria (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Actinobacteria (phylum), Proteobacteria (phylum), Firmicutes (phylum), Verrucomicrobia (phylum), and/or any other suitable taxa. Thus, characterization of the subject comprises characterization of the subject as someone with dandruff based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
[0071]Additionally or alternatively, in Block S13o, the set of features can include functional diversity features associated with scalp-related conditions (e.g., associated with dandruff diagnostics using skin samples) and/or other skin-associated conditions, including one or more of: COG derived features, KEGG L2, L3, L4 derived features, and any other suitable functional diversity features. In specific examples, such features can include one or more of: a glycan biosynthesis and metabolism KEGG L2 derived feature, an environmental adaptation KEGG L2 derived feature, a cancers KEGG L2 derived feature, an immune system diseases KEGG L2 derived feature, a transcription derived feature, a signaling molecules and interaction KEGG L2 derived feature, a membrane transport KEGG L2 derived feature, a cell motility KEGG L2 derived feature, a cellular processes and signaling KEGG L2 derived feature, a metabolism of cofactors and vitamins KEGG L2 derived feature, a metabolism KEGG L2 derived feature, a neurodegenerative diseases KEGG L2 derived feature, a metabolic diseases KEGG
derived feature, an enzyme families KEGG L2 derived feature, a cell growth and death KEGG L2 derived feature, a carbohydrate metabolism KEGG L2 derived feature, a transport and catabolism KEGG L2 derived feature, a genetic information processing KEGG L2 derived feature, a replication and repair KEGG L2 derived feature, an energy metabolism KEGG L2 derived feature, a digestive system KEGG L2 derived feature, an amino acid metabolism KEGG L2 derived feature, a metabolism of other amino acids KEGG L2 derived feature, a biosynthesis of other secondary metabolites KEGG L2 derived feature, a folding, sorting and degradation KEGG L2 derived feature, a lipid metabolism KEGG L2 derived feature, an infectious diseases KEGG L2 derived feature, a nucleotide metabolism KEGG L2 derived feature, a metabolism of terpenoids and polyketides KEGG L2 derived feature, a renal cell carcinoma KEGG L3 derived feature, an ubiquinone and other terpenoid-quinone biosynthesis KEGG L3 derived feature, an amyotrophic lateral sclerosis KEGG L3 derived feature, a lipoic acid metabolism KEGG
L3 derived feature, a cyanoamino acid metabolism KEGG L3 derived feature, a glutathione metabolism KEGG L3 derived feature, a toluene degradation KEGG L3 derived feature, a riboflavin metabolism KEGG L3 derived feature, a plant-pathogen interaction KEGG L3 derived feature, a prenyltransferases KEGG L3 derived feature, a biosynthesis of ansamycins KEGG L3 derived feature, an ABC transporters KEGG
derived feature, an inositol phosphate metabolism KEGG L3 derived feature, a citrate cycle (TCA cycle) KEGG L3 derived feature, a chromosome KEGG L3 derived feature, a glycolysis / gluconeogenesis KEGG L3 derived feature, a valine, leucine and isoleucine degradation KEGG L3 derived feature, a primary immunodeficiency KEGG L3 derived feature, a DNA replication proteins KEGG L3 derived feature, a cytoskeleton proteins KEGG L3 derived feature, a peroxisome KEGG L3 derived feature, a transcription machinery KEGG L3 derived feature, a protein folding and associated processing KEGG
L3 derived feature, a d-alanine metabolism KEGG L3 derived feature, a translation proteins KEGG L3 derived feature, a glycine, serine and threonine metabolism derived feature, a lipopolysaccharide biosynthesis proteins KEGG L3 derived feature, an energy metabolism KEGG L3 derived feature, a lipid metabolism KEGG L3 derived feature, a peptidases KEGG L3 derived feature, a carbohydrate digestion and absorption KEGG L3 derived feature, a caprolactam degradation KEGG L3 derived feature, a glycerolipid metabolism KEGG L3 derived feature, a carbon fixation in photosynthetic organisms KEGG L3 derived feature, a membrane and intracellular structural molecules KEGG L3 derived feature, a fatty acid biosynthesis KEGG L3 derived feature, a type I
diabetes mellitus KEGG L3 derived feature, a phosphotransferase system (pts) derived feature, a base excision repair KEGG L3 derived feature, a sporulation derived feature, a transporters KEGG L3 derived feature, a protein kinases derived feature, a pantothenate and CoA biosynthesis KEGG L3 derived feature, a cell cycle - Caulobacter KEGG L3 derived feature, a butirosin and neomycin biosynthesis KEGG L3 derived feature, a mismatch repair KEGG L3 derived feature, a pores ion channels KEGG L3 derived feature, an oxidative phosphorylation KEGG L3 derived feature, a cell division KEGG L3 derived feature, a replication, recombination and repair proteins KEGG L3 derived feature, a bacterial motility proteins KEGG L3 derived feature, a carbon fixation pathways in prokaryotes KEGG L3 derived feature, a transcription factors KEGG L3 derived feature, a vitamin b6 metabolism KEGG L3 derived feature, a chloroalkane and chloroalkene degradation KEGG L3 derived feature, a peptidoglycan biosynthesis KEGG L3 derived feature, a drug metabolism -other enzymes KEGG L3 derived feature, a proteasome KEGG L3 derived feature, a RNA
transport KEGG L3 derived feature, an ascorbate and aldarate metabolism KEGG
derived feature, a cysteine and methionine metabolism KEGG L3 derived feature, a galactose metabolism KEGG L3 derived feature, a tetracycline biosynthesis KEGG
derived feature, a translation factors KEGG L3 derived feature, a glycerophospholipid metabolism KEGG L3 derived feature, a pentose phosphate pathway KEGG L3 derived feature, a tyrosine metabolism KEGG L3 derived feature, a photosynthesis proteins KEGG L3 derived feature, a Vibrio cholerae pathogenic cycle KEGG L3 derived feature, an amino sugar and nucleotide sugar metabolism KEGG L3 derived feature, a bacterial chemotaxis KEGG L3 derived feature, a tryptophan metabolism KEGG L3 derived feature, a nicotinate and nicotinamide metabolism KEGG L3 derived feature, a histidine metabolism KEGG L3 derived feature, a biotin metabolism KEGG L3 derived feature, a secretion system KEGG L3 derived feature, a cellular antigens KEGG L3 derived feature, a sulfur relay system KEGG L3 derived feature, a taurine and hypotaurine metabolism KEGG L3 derived feature, a photosynthesis KEGG L3 derived feature, a zeatin biosynthesis KEGG L3 derived feature, a methane metabolism KEGG L3 derived feature, a RNA degradation KEGG L3 derived feature, a phosphatidylinositol signaling system KEGG L3 derived feature, a glyoxylate and dicarboxylate metabolism KEGG
derived feature, an adipocytokine signaling pathway KEGG L3 derived feature, a starch and sucrose metabolism KEGG L3 derived feature, a chaperones and folding catalysts KEGG L3 derived feature, a vitamin metabolism KEGG L3 derived feature, a pyruvate metabolism KEGG L3 derived feature, a porphyrin and chlorophyll metabolism KEGG
L3 derived feature, a geraniol degradation KEGG L3 derived feature, a tuberculosis KEGG L3 derived feature, a tropane, piperidine and pyridine alkaloid biosynthesis KEGG L3 derived feature, a beta-alanine metabolism KEGG L3 derived feature, a PPAR
signaling pathway KEGG L3 derived feature, a lysine biosynthesis KEGG L3 derived feature, a protein export KEGG L3 derived feature, an arachidonic acid metabolism KEGG L3 derived feature, a thiamine metabolism KEGG L3 derived feature, a phenylpropanoid biosynthesis KEGG L3 derived feature, a ribosome biogenesis KEGG
L3 derived feature, a nucleotide excision repair KEGG L3 derived feature, a synthesis and degradation of ketone bodies KEGG L3 derived feature, a benzoate degradation KEGG L3 derived feature, a sulfur metabolism KEGG L3 derived feature, a metabolism of xenobiotics by cytochrome p450 KEGG L3 derived feature, a penicillin and cephalosporin biosynthesis KEGG L3 derived feature, a drug metabolism -cytochrome p450 KEGG L3 derived feature, a purine metabolism KEGG L3 derived feature, a novobiocin biosynthesis KEGG L3 derived feature, a propanoate metabolism KEGG
derived feature, a limonene and pinene degradation KEGG L3 derived feature, an aminobenzoate degradation KEGG L3 derived feature, a Huntington's disease KEGG
derived feature, a C5-branched dibasic acid metabolism KEGG L3 derived feature, a folate biosynthesis KEGG L3 derived feature, a phenylalanine metabolism KEGG
derived feature, and/or any other suitable combination of features.
derived feature, an enzyme families KEGG L2 derived feature, a cell growth and death KEGG L2 derived feature, a carbohydrate metabolism KEGG L2 derived feature, a transport and catabolism KEGG L2 derived feature, a genetic information processing KEGG L2 derived feature, a replication and repair KEGG L2 derived feature, an energy metabolism KEGG L2 derived feature, a digestive system KEGG L2 derived feature, an amino acid metabolism KEGG L2 derived feature, a metabolism of other amino acids KEGG L2 derived feature, a biosynthesis of other secondary metabolites KEGG L2 derived feature, a folding, sorting and degradation KEGG L2 derived feature, a lipid metabolism KEGG L2 derived feature, an infectious diseases KEGG L2 derived feature, a nucleotide metabolism KEGG L2 derived feature, a metabolism of terpenoids and polyketides KEGG L2 derived feature, a renal cell carcinoma KEGG L3 derived feature, an ubiquinone and other terpenoid-quinone biosynthesis KEGG L3 derived feature, an amyotrophic lateral sclerosis KEGG L3 derived feature, a lipoic acid metabolism KEGG
L3 derived feature, a cyanoamino acid metabolism KEGG L3 derived feature, a glutathione metabolism KEGG L3 derived feature, a toluene degradation KEGG L3 derived feature, a riboflavin metabolism KEGG L3 derived feature, a plant-pathogen interaction KEGG L3 derived feature, a prenyltransferases KEGG L3 derived feature, a biosynthesis of ansamycins KEGG L3 derived feature, an ABC transporters KEGG
derived feature, an inositol phosphate metabolism KEGG L3 derived feature, a citrate cycle (TCA cycle) KEGG L3 derived feature, a chromosome KEGG L3 derived feature, a glycolysis / gluconeogenesis KEGG L3 derived feature, a valine, leucine and isoleucine degradation KEGG L3 derived feature, a primary immunodeficiency KEGG L3 derived feature, a DNA replication proteins KEGG L3 derived feature, a cytoskeleton proteins KEGG L3 derived feature, a peroxisome KEGG L3 derived feature, a transcription machinery KEGG L3 derived feature, a protein folding and associated processing KEGG
L3 derived feature, a d-alanine metabolism KEGG L3 derived feature, a translation proteins KEGG L3 derived feature, a glycine, serine and threonine metabolism derived feature, a lipopolysaccharide biosynthesis proteins KEGG L3 derived feature, an energy metabolism KEGG L3 derived feature, a lipid metabolism KEGG L3 derived feature, a peptidases KEGG L3 derived feature, a carbohydrate digestion and absorption KEGG L3 derived feature, a caprolactam degradation KEGG L3 derived feature, a glycerolipid metabolism KEGG L3 derived feature, a carbon fixation in photosynthetic organisms KEGG L3 derived feature, a membrane and intracellular structural molecules KEGG L3 derived feature, a fatty acid biosynthesis KEGG L3 derived feature, a type I
diabetes mellitus KEGG L3 derived feature, a phosphotransferase system (pts) derived feature, a base excision repair KEGG L3 derived feature, a sporulation derived feature, a transporters KEGG L3 derived feature, a protein kinases derived feature, a pantothenate and CoA biosynthesis KEGG L3 derived feature, a cell cycle - Caulobacter KEGG L3 derived feature, a butirosin and neomycin biosynthesis KEGG L3 derived feature, a mismatch repair KEGG L3 derived feature, a pores ion channels KEGG L3 derived feature, an oxidative phosphorylation KEGG L3 derived feature, a cell division KEGG L3 derived feature, a replication, recombination and repair proteins KEGG L3 derived feature, a bacterial motility proteins KEGG L3 derived feature, a carbon fixation pathways in prokaryotes KEGG L3 derived feature, a transcription factors KEGG L3 derived feature, a vitamin b6 metabolism KEGG L3 derived feature, a chloroalkane and chloroalkene degradation KEGG L3 derived feature, a peptidoglycan biosynthesis KEGG L3 derived feature, a drug metabolism -other enzymes KEGG L3 derived feature, a proteasome KEGG L3 derived feature, a RNA
transport KEGG L3 derived feature, an ascorbate and aldarate metabolism KEGG
derived feature, a cysteine and methionine metabolism KEGG L3 derived feature, a galactose metabolism KEGG L3 derived feature, a tetracycline biosynthesis KEGG
derived feature, a translation factors KEGG L3 derived feature, a glycerophospholipid metabolism KEGG L3 derived feature, a pentose phosphate pathway KEGG L3 derived feature, a tyrosine metabolism KEGG L3 derived feature, a photosynthesis proteins KEGG L3 derived feature, a Vibrio cholerae pathogenic cycle KEGG L3 derived feature, an amino sugar and nucleotide sugar metabolism KEGG L3 derived feature, a bacterial chemotaxis KEGG L3 derived feature, a tryptophan metabolism KEGG L3 derived feature, a nicotinate and nicotinamide metabolism KEGG L3 derived feature, a histidine metabolism KEGG L3 derived feature, a biotin metabolism KEGG L3 derived feature, a secretion system KEGG L3 derived feature, a cellular antigens KEGG L3 derived feature, a sulfur relay system KEGG L3 derived feature, a taurine and hypotaurine metabolism KEGG L3 derived feature, a photosynthesis KEGG L3 derived feature, a zeatin biosynthesis KEGG L3 derived feature, a methane metabolism KEGG L3 derived feature, a RNA degradation KEGG L3 derived feature, a phosphatidylinositol signaling system KEGG L3 derived feature, a glyoxylate and dicarboxylate metabolism KEGG
derived feature, an adipocytokine signaling pathway KEGG L3 derived feature, a starch and sucrose metabolism KEGG L3 derived feature, a chaperones and folding catalysts KEGG L3 derived feature, a vitamin metabolism KEGG L3 derived feature, a pyruvate metabolism KEGG L3 derived feature, a porphyrin and chlorophyll metabolism KEGG
L3 derived feature, a geraniol degradation KEGG L3 derived feature, a tuberculosis KEGG L3 derived feature, a tropane, piperidine and pyridine alkaloid biosynthesis KEGG L3 derived feature, a beta-alanine metabolism KEGG L3 derived feature, a PPAR
signaling pathway KEGG L3 derived feature, a lysine biosynthesis KEGG L3 derived feature, a protein export KEGG L3 derived feature, an arachidonic acid metabolism KEGG L3 derived feature, a thiamine metabolism KEGG L3 derived feature, a phenylpropanoid biosynthesis KEGG L3 derived feature, a ribosome biogenesis KEGG
L3 derived feature, a nucleotide excision repair KEGG L3 derived feature, a synthesis and degradation of ketone bodies KEGG L3 derived feature, a benzoate degradation KEGG L3 derived feature, a sulfur metabolism KEGG L3 derived feature, a metabolism of xenobiotics by cytochrome p450 KEGG L3 derived feature, a penicillin and cephalosporin biosynthesis KEGG L3 derived feature, a drug metabolism -cytochrome p450 KEGG L3 derived feature, a purine metabolism KEGG L3 derived feature, a novobiocin biosynthesis KEGG L3 derived feature, a propanoate metabolism KEGG
derived feature, a limonene and pinene degradation KEGG L3 derived feature, an aminobenzoate degradation KEGG L3 derived feature, a Huntington's disease KEGG
derived feature, a C5-branched dibasic acid metabolism KEGG L3 derived feature, a folate biosynthesis KEGG L3 derived feature, a phenylalanine metabolism KEGG
derived feature, and/or any other suitable combination of features.
[0072] However, performing the characterization process for in particular dandruff condition and/or any other scalp-related conditions can be performed in any suitable manner using any suitable features.
4.2.D Characterization Process ¨ Pimple-related Condition
4.2.D Characterization Process ¨ Pimple-related Condition
[0073] In variations of Block S13o, performing a characterization process can be for one or more pimple-related conditions. In particular, pimple-related conditions can include any suitable acne-related conditions.
[0074]In variations, a set of features for characterizations of pimple-related and/or other skin-related conditions can include features including and/or otherwise derived from one or more of the following taxa: Lactobacillales, and/or any other suitable taxa.
[0075]In relation to Block S13o, additionally or alternatively, the set of features associated can include functional diversity features including and/or otherwise derived from one or more of: COG derived features, KEGG L2, L3, L4 derived features, and any other suitable functional diversity features, and/or any other suitable features.
4.2.E Characterization Process ¨ Eczema.
4.2.E Characterization Process ¨ Eczema.
[0076] In variations of Block S13o, performing a characterization process can be for one or more eczema conditions. In particular eczema can include a skin condition characterized by skin inflammation. In an example eczema can be characterized by non-microbiome-based tests.
[0077] In variations, a set of features for characterizations of eczema and/or other skin-related conditions can include features including and/or otherwise derived from one or more of the following taxa: Streptococcaceae, Streptococcus, Lactobacillales, Veillonella, and/or any other suitable taxa.
[0078]In relation to Block S13o, additionally or alternatively, the set of features associated can include functional diversity features including and/or otherwise derived from one or more of: COG derived features, KEGG L2, L3, L4 derived features, and any other suitable functional diversity features, and/or any other suitable features.
[0079] Thus, characterization of the subject can include characterization of the subject as someone with one or more skin-related conditions based upon detection of one or more of the above features, in a manner that is an alternative or supplemental to typical methods of diagnosis. In variations of the specific example, the set of features can, however, include any other suitable features useful for diagnostics.
4.3 Method ¨ Personalization to a User.
4.3 Method ¨ Personalization to a User.
[0080] The method 100 can additionally or alternatively include Block S14o, which recites: determining a therapy for preventing, ameliorating, and/or otherwise modifying a skin-related condition. Block S14o functions to identify and/or predict therapies (e.g., probiotic-based therapies, phage-based therapies, small molecule-based therapies, etc.) that can shift a user's microbiome composition and/or functional diversity features toward a desired equilibrium state in promotion of the user's health. Block S14o can additionally or alternatively include generating and/or applying a therapy model for determining the therapy. In Block S14o, the therapies can be selected from therapies including one or more of: probiotic therapies, prebiotic therapies, antibiotic therapies, antifungal therapies, phage-based therapies, small molecule-based therapies, cognitive/behavioral therapies, physical therapies (e.g., physical rehabilitation, bathing hygiene, daily hygiene, etc.), clinical therapies, medication-based therapies, topical application-based therapies (e.g., salicylic acid, benzoyl peroxide, vitamin A
creams, moisturizer, steroid creams, antihistamines, shampoo, lotions, oils, creams, etc.), alternative medicine-based therapies, environmental-based therapies (e.g., light-based therapies, temperature-based therapies, etc.), diet-related therapies, and/or any other suitable therapy designed to operate in any other suitable manner in promoting a user's health. In a specific example of a bacteriophage-based therapy, one or more populations (e.g., in terms of colony forming units) of bacteriophages specific to a certain bacteria (or other microorganism) represented in the user can be used to down-regulate or otherwise eliminate populations of the certain bacteria. As such, bacteriophage-based therapies can be used to reduce the size(s) of the undesired population(s) of bacteria represented in the user. Complementarily, bacteriophage-based therapies can be used to increase the relative abundances of bacterial populations not targeted by the bacteriophage(s) used. In a variation, Blocks S14o and/or S17o can include automatically initiating a signal that controls a treatment system to promote the therapy (e.g., based on a characterization, a therapy model output, etc.), where initiating the signal can include one or more of: generating and transmitting control instructions to a treatment system (e.g., controlling a probiotic dispensing system to provide a probiotic to a user, etc.), initiating notification provision (e.g., to inform a user regarding one or more characterizations and/or therapies, etc.), and/or any other suitable operation in controlling treatment systems to promote therapies.
[0081 ] In another specific example, Block S14o can include facilitating an interaction between a user and a care provider (e.g., scheduling an appointment with a care provider; initiating a telemedicine conference over a wireless communication channel, as shown in FIGURE 6; etc.), such as in response to and/or concurrently with a trigger condition (e.g., characterizing a skin-related condition risk exceeding a threshold;
manual request by a user or care provider; identifying an effectiveness score below a threshold based on analysis of post-therapy biological samples; etc.).
[0082] Regarding Block S14o, in another specific example of probiotic therapies, as shown in FIGURE 7, candidate therapies of the therapy model can perform one or more of: blocking pathogen entry into an epithelial cell by providing a physical barrier (e.g., by way of colonization resistance), inducing formation of a mucous barrier by stimulation of goblet cells, enhance integrity of apical tight junctions between epithelial cells of a user (e.g., by stimulating up regulation of zona-occludens 1, by preventing tight junction protein redistribution), producing antimicrobial factors, stimulating production of anti-inflammatory cytokines (e.g., by signaling of dendritic cells and induction of regulatory T-cells), triggering an immune response, and performing any other suitable function that adjusts a user's microbiome away from a state of dysbiosis.
[0083] In variations, Block S14o can include generating a therapy model based upon data from a large population of users, which can include the population of users from which the microbiome datasets are derived (e.g., in Block Silo), where microbiome composition and/or functional features or states of health, prior exposure to and post exposure to a variety of therapeutic measures, are well characterized. Such data can be used to train and validate the therapy provision model, in identifying therapeutic measures that provide desired outcomes for users based upon different microbiome characterizations. Additionally or alternatively, generating (and/or applying) a therapy model can be based on characterizations outputted from one or more characterization models. In variations, therapy models, characterization models, and/or other suitable models can leverage machine learning approaches analogous to those described in U.S.
App. No. 15/374,890 filed 09-DEC-2016, which is herein incorporated in its entirety by this reference. In a variation, generating and/or applying a therapy model can be based on one or more causes for a skin-related condition (e.g., a cause of a skin-related condition risk). For example, the method 100 can include: generating a characterization including a skin-related condition risk (e.g., for any suitable skin-related condition);
determining a cause for the skin-related condition risk based on at least one microbiome dataset (e.g., a user microbiome composition feature and a user microbiome functional diversity feature extracted from microbiome datasets); and determining the therapy based on the cause, where the therapy can be operable to reduce the skin-related condition risk. However, therapy models and/or other suitable models (e.g., characterization models) can include any one or more probabilistic properties, heuristic properties, deterministic properties, and/or any other suitable properties, and/or can be configured in any suitable manner.
[0084] Regarding Block S14o, processing of therapy models can be analogous to processing of characterization models (e.g., described for Block S13o), where any number and/or types of treatment models can be generated for different purposes. In a variation, the therapy model can be derived in relation to identification of a "normal" or baseline microbiome composition and/or functional features, as assessed from users of a population of users who are identified to be in good health. Upon identification of a subset of users of the population of users who are characterized to be in good health (e.g., using features of the characterization process), therapies that modulate microbiome compositions and/or functional features toward those of users in good health can be generated in Block S14o. Block S14o can thus include identification of one or more baseline microbiome compositions and/or functional features (e.g., one baseline microbiome for each of a set of demographics), and potential therapy formulations and therapy regimens that can shift microbiomes of users who are in a state of dysbiosis toward one of the identified baseline microbiome compositions and/or functional features. The therapy model can, however, be generated and/or refined in any other suitable manner.
[0085] In relation to Block S14o, microorganism compositions associated with probiotic therapies associated with the therapy model preferably include microorganisms that are culturable (e.g., able to be expanded to provide a scalable therapy) and non-lethal (e.g., non-lethal in their desired therapeutic dosages). Furthermore, microorganism compositions can include a single type of microorganism that has an acute or moderated effect upon a user's microbiome. Additionally or alternatively, microorganism compositions can include balanced combinations of multiple types of microorganisms that are configured to cooperate with each other in driving a user's microbiome toward a desired state. For instance, a combination of multiple types of bacteria in a probiotic therapy can include a first bacteria type that generates products that are used by a second bacteria type that has a strong effect in positively affecting a user's microbiome.
Additionally or alternatively, a combination of multiple types of bacteria in a probiotic therapy can include several bacteria types that produce proteins with the same functions that positively affect a user's microbiome.
[0086] Regarding Block S14o, probiotic compositions can be naturally or synthetically derived. For instance, in one application, a probiotic composition can be naturally derived from fecal matter or other biological matter (e.g., of one or more users having a baseline microbiome composition and/or functional features, as identified using the characterization process and the therapy model). Additionally or alternatively, probiotic compositions can be synthetically derived (e.g., derived using a benchtop method) based upon a baseline microbiome composition and/or functional features, as identified using the characterization process and the therapy model. In variations, microorganism agents that can be used in probiotic therapies can include one or more of:
yeast (e.g., Saccharomyces boulardii), gram-negative bacteria (e.g., E. coli Nissle, Akkermansia rnuciniphila, Prevotella bryantii, etc.), gram-positive bacteria (e.g., Bifidobacteriurn animalis (including subspecies lactis), Bifidobacterium ion gum (including subspecies infantis), Bifidobacterium bifidum, Bffldobacterium pseudolongurn, Bifidobacterium therrnophilum, Bifidobacteriurn breve, Lactobacillus rharnnosus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus salivarius, Lactobacillus delbrueckii (including subspecies bulgaricus), Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus brevis (including subspecies coagulans), Bacillus cereus, Bacillus sub tilis (including var. Natto), Bacillus polyfermenticus, Bacillus clausii, Bacillus licheniformis, Bacillus coagulans, Bacillus pumilus, Faecalibacterium prausnitzii, Streptococcus thermophiles, Brevibacillus brevis, Lactococcus lactis, Leuconostoc mesenteroides, Enterococcus faecium, Enterococcus faecalis, Enterococcus durans, Clostridium butyricum, Sporolactobacillus inulinus, Sporolactobacillus vineae, Pediococcus acidilactic, Pediococcus pentosaceus, etc.), and/or any other suitable type of microorganism agent.
[0087] In a variation of Block Sizio, for users who exhibit photosensitivity, dry skin or dandruff and/or other skin-related conditions, a probiotic therapy can include a combination of one or more of: Bacteroidetes (phylum), Propionibacterium (genus), Staphylococcus (genus), Corynebacterium (genus), Streptococcus (genus) provided at dosages of 1 million to 10 billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy. In another variation of Block S14o, for users who exhibit Eczema and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of: Streptococcaceae, Streptococcus, Lactobacillales, Veillonella provided at dosages of 1 million to 10 billion CFUs, and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy. In another variation, for users who exhibit dry skin and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more microorganisms from: Actinobacteria (class), Actinobacteria (phylum), Propionibacterium (genus) provided at dosages of 1 million to billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
In another variation, for users who exhibit dandruff and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of:
Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Prevotella (genus), Porphyromonadaceae (family), Lachnospiraceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Selenomonadales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Pasteurellales (order), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Proteobacteria (phylum), Firmicutes (phylum), Propionibacterium (genus), Staphylococcus (genus) provided at dosages of 1 million to billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
In another variation, for users who exhibit Pimples and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of:
Lactobacillales provided at dosages of 1 million to 10 billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
[0088] In specific examples of Block S14o, a user can be instructed to ingest capsules including the probiotic formulation according to a regimen tailored to one or more of his/her: physiology (e.g., body mass index, weight, height), demographics (e.g., gender, age), severity of dysbiosis, sensitivity to medications, and any other suitable factor.
[0089]Additionally or alternatively, regarding Block Sizio, therapies promoted by the therapy model of Block Sizio can include one or more of: consumables (e.g., food items, beverage items, nutritional supplements), suggested activities (e.g., exercise regimens, adjustments to alcohol consumption, adjustments to cigarette usage, adjustments to drug usage), topical therapies (e.g., lotions, ointments, antiseptics, etc.), adjustments to hygienic product usage (e.g., use of shampoo products, use of conditioner products, use of soaps, use of makeup products, etc.), adjustments to diet (e.g., sugar consumption, fat consumption, salt consumption, acid consumption, etc.), adjustments to sleep behavior, living arrangement adjustments (e.g., adjustments to living with pets, adjustments to living with plants in one's home environment, adjustments to light and temperature in one's home environment, etc.), nutritional supplements (e.g., vitamins, minerals, fiber, fatty acids, amino acids, prebiotics, probiotics, etc.), medications, antibiotics, and any other suitable therapeutic measure. Among the prebiotics suitable for treatment, as either part of any food or as supplement, are included the following components: 1,4-dihydroxy-2-naphthoic acid (DHNA), Inulin, trans-Galactooligosaccharides (GOS), Lactulose, Mannan oligosaccharides (MOS), Fructooligosaccharides (FOS), Neoagaro-oligosaccharides (NAOS), Pyrodextrins, Xylo-oligosaccharides (XOS), Isomalto-oligosaccharides (IMOS), Amylose-resistant starch, Soybean oligosaccharide (SBOS), Lactitol, Lactosucrose (LS), Isomaltulose (including Palatinose), Arabinoxylooligosaccharides (AXOS), Raffinose oligosaccharides (RFO), Arabinoxylans (AX), Polyphenols or any other compound capable of changing the microbiota composition with a desirable effect. In a variation, Blocks Sizio and/or S17o can include deriving a therapeutic composition associated with at least one of a microbiome composition and/or functional diversity dataset (e.g., extracted features).
For example, the method 100 can include determining a modulator of a biomolecule associated with the skin-related condition (e.g., a modulator of a biomolecule derived from a set of taxa associated with the skin-related condition); deriving a therapeutic composition for the skin-related condition based on the modulator; and promoting the therapeutic composition.
[0090] The method loo can additionally or alternatively include Block S15o, which recites: receiving a biological sample from a user. Block S15o functions to facilitate generation of a microbiome dataset for the user that can be used to derive inputs for the characterization process. As such, receiving, processing, and analyzing the biological sample preferably facilitates generation of a microbiome dataset for the user, which can be used to provide inputs for a characterization process. In Block S15o, the biological sample is preferably generated from the user and/or an environment of the user in a non-invasive manner (e.g., using a provided sample kit, etc.), but can additionally or alternatively be received in a semi-invasive manner, invasive manner, and/or in any suitable manner.
[0091 ] Furthermore, in Block S15o, processing and analyzing the biological sample from the user is preferably performed in a manner similar to that of one of the embodiments, variations, and/or examples of sample processing described in relation to Block Silo above, and/or in U.S. App. No. 15/452,529 filed 07-MAR-2017, which is incorporated in its entirety by this reference. However, biological sample reception and processing in Block S15o can alternatively be performed in any other suitable manner.
[0092]As shown in FIGURE 3, the method can additionally or alternatively include Block 5160, which recites: determining, with the characterization process, a characterization of the user based upon processing a microbiome dataset derived from a biological sample of the user. Block 5160 can function to extract features from microbiome-derived data of the user (e.g., based on evaluating the microbiome datasets against computer-implemented rules), and use the features as inputs into an embodiment, variation, or example of the characterization process (e.g., a characterization model) described in Block S13o above. Identifying the characterization in Block 5160 thus preferably includes identifying features and/or combinations of features associated with the microbiome composition and/or functional features of the user, inputting the features into the characterization process, and receiving an output that characterizes the user as belonging to one or more of: a behavioral group, a gender group, a dietary group, a disease-state group, and/or any other suitable group capable of being identified by the characterization process. Block Si6o can further include generation of and/or output of a confidence metric associated with the characterization of the user. For instance, a confidence metric can be derived from the number of features used to generate the characterization, relative weights or rankings of features used to generate the characterization, measures of bias in the characterization process, and/or any other suitable parameter associated with aspects of the characterization process. In some variations, features extracted from the microbiome dataset of the user can be supplemented with survey-derived and/or medical history-derived features from the user, which can be used to further refine the characterization process of Block S13o.
However, the microbiome dataset of the user can additionally or alternatively be used in any other suitable manner to enhance the models of the method loo, and Block Si6o can be performed in any suitable manner.
4.4 Method - Promoting and Monitoring a Therapy.
[0093] As shown in FIGURE 6, the method 100 can additionally or alternatively include Block S17o, which recites: promoting a therapy for the skin-related condition to the user (e.g., based upon the characterization, a therapy model, etc.). Block S17o functions to determine, recommend, and/or provide a personalized therapy to the user, in order to shift the microbiome composition and/or functional features of the user toward a desired equilibrium state. Block S17o can include provision of a customized therapy to the user according to their microbiome composition and functional features, as shown in FIGURE 8, where the customized therapy is a formulation of microorganisms configured to correct dysbiosis characteristic of users having the identified characterization. As such, outputs of Block S14o can be used to directly promote a customized therapy formulation and regimen (e.g., dosage, usage instructions) to the user based upon a trained therapy model. Additionally or alternatively, therapy provision can include recommendation of available therapeutic measures configured to shift microbiome composition and/or functional features toward a desired state. In variations, available therapeutic measures can include one or more of:
consumables (e.g., food items, beverage items, etc.), topical therapies (e.g., lotions, ointments, antiseptics, etc.), nutritional supplements (e.g., vitamins, minerals, fiber, fatty acids, amino acids, prebiotics, etc.), medications, antibiotics, bacteriophages, and any other suitable therapeutic measure. For instance, a combination of commercially available probiotic supplements can include a suitable probiotic therapy for the user according to an output of the therapy model.
[0094] Additionally or alternatively, in a specific example, the therapy of Block S17o can include a bacteriophage-based therapy. In more detail, one or more populations (e.g., in terms of colony forming units) of bacteriophages specific to a certain bacteria (or other microorganism) represented in the user can be used to down-regulate or otherwise eliminate populations of the certain bacteria. As such, bacteriophage-based therapies can be used to reduce the size(s) of the undesired population(s) of bacteria represented in the user. Complementarily, bacteriophage-based therapies can be used to increase the relative abundances of bacterial populations not targeted by the bacteriophage(s) used.
[0095] Therapy provision in Block S17o can include provision of notifications to a user regarding the recommended therapy and/or other forms of therapy. Types of notifications and manners of providing notifications can be analogous to that described in U.S. App. No. 15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
[0096] As shown in FIGURE 4, the method 100 can additionally or alternatively include Block Si8o, which recites: monitoring effectiveness of the therapy for the user, based upon processing biological samples, to assess microbiome composition and/or functional diversity for the user over time. Block Si8o functions to gather additional data regarding positive effects, negative effects, and/or lack of effectiveness of a probiotic therapy suggested by the therapy model for users of a given characterization, where the additional data can be used, for example, to generate, update, and/or execute one or more characterization models, therapy models, and/or other suitable models. For example, the method loo can include updating a model (e.g., characterization model, therapy model, etc.) based one or more of a user microbiome composition dataset (e.g., features extracted from the dataset, etc.), a user microbiome functional diversity dataset (e.g., features extracted from the dataset, etc.), and/or other suitable dataset (e.g., updating a model based on modulation of the skin-related condition, determined based on comparisons of pre-therapy and post-therapy microbiome datasets); and in response to updating the model, determining an update (e.g., to a characterization, to a therapy, etc.) for a second user in relation to the skin-related condition, based on the updated model. In another example, the method loo can include: receiving a post-therapy biological sample from the user (e.g., after promoting the therapy);
generating a post-therapy characterization of the user in relation to the skin-related condition based on the post-therapy biological sample (e.g., post-therapy microbiome composition and/or functional diversity features extracted from the post-therapy biological sample using skin-related feature- selection rules, where the features can be used with a characterization model, etc.); characterizing modulation of the skin-related condition in relation to the user based on the post-therapy characterization (e.g., and one or more pre-therapy characterizations for the user, for a second user, etc.). However, any suitable portion of the method loo and/or any suitable operation can be performed in response to updating of models. Monitoring of a user during the course of a therapy promoted by the therapy model (e.g., by receiving and analyzing biological samples from the user throughout therapy, by receiving survey-derived data from the user throughout therapy) can thus be used to generate a therapy-effectiveness model for each characterization provided by the characterization process of Block S13o, and each recommended therapy measure provided in Blocks S14o and S17o.
[0097] In Block Si8o, the user can be prompted to provide additional biological samples at one or more key time points of a therapy regimen that incorporates the therapy, and the additional biological sample(s) can be processed and analyzed (e.g., in a manner similar to that described in relation to Block S12o) to generate metrics characterizing modulation of the user's microbiome composition and/or functional features.
For instance, metrics related to one or more of: a change in relative abundance of one or more taxonomic groups represented in the user's microbiome at an earlier time point, a change in representation of a specific taxonomic group of the user's microbiome, a ratio between abundance of a first taxonomic group of bacteria and abundance of a second taxonomic group of bacteria of the user's microbiome, a change in relative abundance of one or more functional families in a user's microbiome, and any other suitable metrics can be used to assess therapy effectiveness from changes in microbiome composition and/or functional features. Additionally or alternatively, survey-derived data from the user, pertaining to experiences of the user while on the therapy (e.g., experienced side effects, personal assessment of improvement, etc.) can be used to determine effectiveness of the therapy in Block Si80. However, monitoring effectiveness of one or more therapies can be performed in any suitable manner.
[0098] The method 100 can, however, include any other suitable blocks or steps configured to facilitate reception of biological samples from users, processing of biological samples from users, analyzing data derived from biological samples, and generating models that can be used to provide customized diagnostics and/or probiotic-based therapeutics according to specific microbiome compositions and/or functional features of users.
[0099] The method loo and/or system of the embodiments can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions. The instructions can be executed by computer-executable components integrated with the application, applet, host, server, network, website, communication service, communication interface, hardware/firmware/software elements of a patient computer or mobile device, or any suitable combination thereof. Other systems and methods of the embodiments can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions. The instructions can be executed by computer-executable components integrated by computer-executable components integrated with apparatuses and networks of the type described above. The computer-readable medium can be stored on any suitable computer readable media such as RAMs, ROMs, flash memory, EEPROMs, optical devices (CD or DVD), hard drives, floppy drives, or any suitable device. The computer-executable component can be a processor, though any suitable dedicated hardware device can (alternatively or additionally) execute the instructions.
[00100] The FIGURES illustrate the architecture, functionality and operation of possible implementations of systems, methods and computer program products according to preferred embodiments, example configurations, and variations thereof. In this regard, each block in the flowchart or block diagrams may represent a module, segment, step, or portion of code, which includes one or more executable instructions for implementing the specified logical function(s). It should also be noted that, in some alternative implementations, the functions noted in the block can occur out of the order noted in the FIGURES. For example, two blocks shown in succession may, in fact, be executed substantially concurrently, or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved. It will also be noted that each block of the block diagrams and/or flowchart illustration, and combinations of blocks in the block diagrams and/or flowchart illustration, can be implemented by special purpose hardware-based systems that perform the specified functions or acts, or combinations of special purpose hardware and computer instructions.
[00101] The embodiments include every combination and permutation of the various system components and the various method processes, including any variations, examples, and specific examples.
[00102] As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the embodiments of the invention without departing from the scope of this invention as defined in the following claims.
creams, moisturizer, steroid creams, antihistamines, shampoo, lotions, oils, creams, etc.), alternative medicine-based therapies, environmental-based therapies (e.g., light-based therapies, temperature-based therapies, etc.), diet-related therapies, and/or any other suitable therapy designed to operate in any other suitable manner in promoting a user's health. In a specific example of a bacteriophage-based therapy, one or more populations (e.g., in terms of colony forming units) of bacteriophages specific to a certain bacteria (or other microorganism) represented in the user can be used to down-regulate or otherwise eliminate populations of the certain bacteria. As such, bacteriophage-based therapies can be used to reduce the size(s) of the undesired population(s) of bacteria represented in the user. Complementarily, bacteriophage-based therapies can be used to increase the relative abundances of bacterial populations not targeted by the bacteriophage(s) used. In a variation, Blocks S14o and/or S17o can include automatically initiating a signal that controls a treatment system to promote the therapy (e.g., based on a characterization, a therapy model output, etc.), where initiating the signal can include one or more of: generating and transmitting control instructions to a treatment system (e.g., controlling a probiotic dispensing system to provide a probiotic to a user, etc.), initiating notification provision (e.g., to inform a user regarding one or more characterizations and/or therapies, etc.), and/or any other suitable operation in controlling treatment systems to promote therapies.
[0081 ] In another specific example, Block S14o can include facilitating an interaction between a user and a care provider (e.g., scheduling an appointment with a care provider; initiating a telemedicine conference over a wireless communication channel, as shown in FIGURE 6; etc.), such as in response to and/or concurrently with a trigger condition (e.g., characterizing a skin-related condition risk exceeding a threshold;
manual request by a user or care provider; identifying an effectiveness score below a threshold based on analysis of post-therapy biological samples; etc.).
[0082] Regarding Block S14o, in another specific example of probiotic therapies, as shown in FIGURE 7, candidate therapies of the therapy model can perform one or more of: blocking pathogen entry into an epithelial cell by providing a physical barrier (e.g., by way of colonization resistance), inducing formation of a mucous barrier by stimulation of goblet cells, enhance integrity of apical tight junctions between epithelial cells of a user (e.g., by stimulating up regulation of zona-occludens 1, by preventing tight junction protein redistribution), producing antimicrobial factors, stimulating production of anti-inflammatory cytokines (e.g., by signaling of dendritic cells and induction of regulatory T-cells), triggering an immune response, and performing any other suitable function that adjusts a user's microbiome away from a state of dysbiosis.
[0083] In variations, Block S14o can include generating a therapy model based upon data from a large population of users, which can include the population of users from which the microbiome datasets are derived (e.g., in Block Silo), where microbiome composition and/or functional features or states of health, prior exposure to and post exposure to a variety of therapeutic measures, are well characterized. Such data can be used to train and validate the therapy provision model, in identifying therapeutic measures that provide desired outcomes for users based upon different microbiome characterizations. Additionally or alternatively, generating (and/or applying) a therapy model can be based on characterizations outputted from one or more characterization models. In variations, therapy models, characterization models, and/or other suitable models can leverage machine learning approaches analogous to those described in U.S.
App. No. 15/374,890 filed 09-DEC-2016, which is herein incorporated in its entirety by this reference. In a variation, generating and/or applying a therapy model can be based on one or more causes for a skin-related condition (e.g., a cause of a skin-related condition risk). For example, the method 100 can include: generating a characterization including a skin-related condition risk (e.g., for any suitable skin-related condition);
determining a cause for the skin-related condition risk based on at least one microbiome dataset (e.g., a user microbiome composition feature and a user microbiome functional diversity feature extracted from microbiome datasets); and determining the therapy based on the cause, where the therapy can be operable to reduce the skin-related condition risk. However, therapy models and/or other suitable models (e.g., characterization models) can include any one or more probabilistic properties, heuristic properties, deterministic properties, and/or any other suitable properties, and/or can be configured in any suitable manner.
[0084] Regarding Block S14o, processing of therapy models can be analogous to processing of characterization models (e.g., described for Block S13o), where any number and/or types of treatment models can be generated for different purposes. In a variation, the therapy model can be derived in relation to identification of a "normal" or baseline microbiome composition and/or functional features, as assessed from users of a population of users who are identified to be in good health. Upon identification of a subset of users of the population of users who are characterized to be in good health (e.g., using features of the characterization process), therapies that modulate microbiome compositions and/or functional features toward those of users in good health can be generated in Block S14o. Block S14o can thus include identification of one or more baseline microbiome compositions and/or functional features (e.g., one baseline microbiome for each of a set of demographics), and potential therapy formulations and therapy regimens that can shift microbiomes of users who are in a state of dysbiosis toward one of the identified baseline microbiome compositions and/or functional features. The therapy model can, however, be generated and/or refined in any other suitable manner.
[0085] In relation to Block S14o, microorganism compositions associated with probiotic therapies associated with the therapy model preferably include microorganisms that are culturable (e.g., able to be expanded to provide a scalable therapy) and non-lethal (e.g., non-lethal in their desired therapeutic dosages). Furthermore, microorganism compositions can include a single type of microorganism that has an acute or moderated effect upon a user's microbiome. Additionally or alternatively, microorganism compositions can include balanced combinations of multiple types of microorganisms that are configured to cooperate with each other in driving a user's microbiome toward a desired state. For instance, a combination of multiple types of bacteria in a probiotic therapy can include a first bacteria type that generates products that are used by a second bacteria type that has a strong effect in positively affecting a user's microbiome.
Additionally or alternatively, a combination of multiple types of bacteria in a probiotic therapy can include several bacteria types that produce proteins with the same functions that positively affect a user's microbiome.
[0086] Regarding Block S14o, probiotic compositions can be naturally or synthetically derived. For instance, in one application, a probiotic composition can be naturally derived from fecal matter or other biological matter (e.g., of one or more users having a baseline microbiome composition and/or functional features, as identified using the characterization process and the therapy model). Additionally or alternatively, probiotic compositions can be synthetically derived (e.g., derived using a benchtop method) based upon a baseline microbiome composition and/or functional features, as identified using the characterization process and the therapy model. In variations, microorganism agents that can be used in probiotic therapies can include one or more of:
yeast (e.g., Saccharomyces boulardii), gram-negative bacteria (e.g., E. coli Nissle, Akkermansia rnuciniphila, Prevotella bryantii, etc.), gram-positive bacteria (e.g., Bifidobacteriurn animalis (including subspecies lactis), Bifidobacterium ion gum (including subspecies infantis), Bifidobacterium bifidum, Bffldobacterium pseudolongurn, Bifidobacterium therrnophilum, Bifidobacteriurn breve, Lactobacillus rharnnosus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus salivarius, Lactobacillus delbrueckii (including subspecies bulgaricus), Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus brevis (including subspecies coagulans), Bacillus cereus, Bacillus sub tilis (including var. Natto), Bacillus polyfermenticus, Bacillus clausii, Bacillus licheniformis, Bacillus coagulans, Bacillus pumilus, Faecalibacterium prausnitzii, Streptococcus thermophiles, Brevibacillus brevis, Lactococcus lactis, Leuconostoc mesenteroides, Enterococcus faecium, Enterococcus faecalis, Enterococcus durans, Clostridium butyricum, Sporolactobacillus inulinus, Sporolactobacillus vineae, Pediococcus acidilactic, Pediococcus pentosaceus, etc.), and/or any other suitable type of microorganism agent.
[0087] In a variation of Block Sizio, for users who exhibit photosensitivity, dry skin or dandruff and/or other skin-related conditions, a probiotic therapy can include a combination of one or more of: Bacteroidetes (phylum), Propionibacterium (genus), Staphylococcus (genus), Corynebacterium (genus), Streptococcus (genus) provided at dosages of 1 million to 10 billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy. In another variation of Block S14o, for users who exhibit Eczema and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of: Streptococcaceae, Streptococcus, Lactobacillales, Veillonella provided at dosages of 1 million to 10 billion CFUs, and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy. In another variation, for users who exhibit dry skin and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more microorganisms from: Actinobacteria (class), Actinobacteria (phylum), Propionibacterium (genus) provided at dosages of 1 million to billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
In another variation, for users who exhibit dandruff and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of:
Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Prevotella (genus), Porphyromonadaceae (family), Lachnospiraceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Selenomonadales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Pasteurellales (order), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Proteobacteria (phylum), Firmicutes (phylum), Propionibacterium (genus), Staphylococcus (genus) provided at dosages of 1 million to billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
In another variation, for users who exhibit Pimples and/or other suitable skin-related conditions, a probiotic therapy can include a combination of one or more of:
Lactobacillales provided at dosages of 1 million to 10 billion CFUs and/or other suitable CFUs, such as determined from a therapy model that predicts positive adjustment of a patient's microbiome in response to the therapy.
[0088] In specific examples of Block S14o, a user can be instructed to ingest capsules including the probiotic formulation according to a regimen tailored to one or more of his/her: physiology (e.g., body mass index, weight, height), demographics (e.g., gender, age), severity of dysbiosis, sensitivity to medications, and any other suitable factor.
[0089]Additionally or alternatively, regarding Block Sizio, therapies promoted by the therapy model of Block Sizio can include one or more of: consumables (e.g., food items, beverage items, nutritional supplements), suggested activities (e.g., exercise regimens, adjustments to alcohol consumption, adjustments to cigarette usage, adjustments to drug usage), topical therapies (e.g., lotions, ointments, antiseptics, etc.), adjustments to hygienic product usage (e.g., use of shampoo products, use of conditioner products, use of soaps, use of makeup products, etc.), adjustments to diet (e.g., sugar consumption, fat consumption, salt consumption, acid consumption, etc.), adjustments to sleep behavior, living arrangement adjustments (e.g., adjustments to living with pets, adjustments to living with plants in one's home environment, adjustments to light and temperature in one's home environment, etc.), nutritional supplements (e.g., vitamins, minerals, fiber, fatty acids, amino acids, prebiotics, probiotics, etc.), medications, antibiotics, and any other suitable therapeutic measure. Among the prebiotics suitable for treatment, as either part of any food or as supplement, are included the following components: 1,4-dihydroxy-2-naphthoic acid (DHNA), Inulin, trans-Galactooligosaccharides (GOS), Lactulose, Mannan oligosaccharides (MOS), Fructooligosaccharides (FOS), Neoagaro-oligosaccharides (NAOS), Pyrodextrins, Xylo-oligosaccharides (XOS), Isomalto-oligosaccharides (IMOS), Amylose-resistant starch, Soybean oligosaccharide (SBOS), Lactitol, Lactosucrose (LS), Isomaltulose (including Palatinose), Arabinoxylooligosaccharides (AXOS), Raffinose oligosaccharides (RFO), Arabinoxylans (AX), Polyphenols or any other compound capable of changing the microbiota composition with a desirable effect. In a variation, Blocks Sizio and/or S17o can include deriving a therapeutic composition associated with at least one of a microbiome composition and/or functional diversity dataset (e.g., extracted features).
For example, the method 100 can include determining a modulator of a biomolecule associated with the skin-related condition (e.g., a modulator of a biomolecule derived from a set of taxa associated with the skin-related condition); deriving a therapeutic composition for the skin-related condition based on the modulator; and promoting the therapeutic composition.
[0090] The method loo can additionally or alternatively include Block S15o, which recites: receiving a biological sample from a user. Block S15o functions to facilitate generation of a microbiome dataset for the user that can be used to derive inputs for the characterization process. As such, receiving, processing, and analyzing the biological sample preferably facilitates generation of a microbiome dataset for the user, which can be used to provide inputs for a characterization process. In Block S15o, the biological sample is preferably generated from the user and/or an environment of the user in a non-invasive manner (e.g., using a provided sample kit, etc.), but can additionally or alternatively be received in a semi-invasive manner, invasive manner, and/or in any suitable manner.
[0091 ] Furthermore, in Block S15o, processing and analyzing the biological sample from the user is preferably performed in a manner similar to that of one of the embodiments, variations, and/or examples of sample processing described in relation to Block Silo above, and/or in U.S. App. No. 15/452,529 filed 07-MAR-2017, which is incorporated in its entirety by this reference. However, biological sample reception and processing in Block S15o can alternatively be performed in any other suitable manner.
[0092]As shown in FIGURE 3, the method can additionally or alternatively include Block 5160, which recites: determining, with the characterization process, a characterization of the user based upon processing a microbiome dataset derived from a biological sample of the user. Block 5160 can function to extract features from microbiome-derived data of the user (e.g., based on evaluating the microbiome datasets against computer-implemented rules), and use the features as inputs into an embodiment, variation, or example of the characterization process (e.g., a characterization model) described in Block S13o above. Identifying the characterization in Block 5160 thus preferably includes identifying features and/or combinations of features associated with the microbiome composition and/or functional features of the user, inputting the features into the characterization process, and receiving an output that characterizes the user as belonging to one or more of: a behavioral group, a gender group, a dietary group, a disease-state group, and/or any other suitable group capable of being identified by the characterization process. Block Si6o can further include generation of and/or output of a confidence metric associated with the characterization of the user. For instance, a confidence metric can be derived from the number of features used to generate the characterization, relative weights or rankings of features used to generate the characterization, measures of bias in the characterization process, and/or any other suitable parameter associated with aspects of the characterization process. In some variations, features extracted from the microbiome dataset of the user can be supplemented with survey-derived and/or medical history-derived features from the user, which can be used to further refine the characterization process of Block S13o.
However, the microbiome dataset of the user can additionally or alternatively be used in any other suitable manner to enhance the models of the method loo, and Block Si6o can be performed in any suitable manner.
4.4 Method - Promoting and Monitoring a Therapy.
[0093] As shown in FIGURE 6, the method 100 can additionally or alternatively include Block S17o, which recites: promoting a therapy for the skin-related condition to the user (e.g., based upon the characterization, a therapy model, etc.). Block S17o functions to determine, recommend, and/or provide a personalized therapy to the user, in order to shift the microbiome composition and/or functional features of the user toward a desired equilibrium state. Block S17o can include provision of a customized therapy to the user according to their microbiome composition and functional features, as shown in FIGURE 8, where the customized therapy is a formulation of microorganisms configured to correct dysbiosis characteristic of users having the identified characterization. As such, outputs of Block S14o can be used to directly promote a customized therapy formulation and regimen (e.g., dosage, usage instructions) to the user based upon a trained therapy model. Additionally or alternatively, therapy provision can include recommendation of available therapeutic measures configured to shift microbiome composition and/or functional features toward a desired state. In variations, available therapeutic measures can include one or more of:
consumables (e.g., food items, beverage items, etc.), topical therapies (e.g., lotions, ointments, antiseptics, etc.), nutritional supplements (e.g., vitamins, minerals, fiber, fatty acids, amino acids, prebiotics, etc.), medications, antibiotics, bacteriophages, and any other suitable therapeutic measure. For instance, a combination of commercially available probiotic supplements can include a suitable probiotic therapy for the user according to an output of the therapy model.
[0094] Additionally or alternatively, in a specific example, the therapy of Block S17o can include a bacteriophage-based therapy. In more detail, one or more populations (e.g., in terms of colony forming units) of bacteriophages specific to a certain bacteria (or other microorganism) represented in the user can be used to down-regulate or otherwise eliminate populations of the certain bacteria. As such, bacteriophage-based therapies can be used to reduce the size(s) of the undesired population(s) of bacteria represented in the user. Complementarily, bacteriophage-based therapies can be used to increase the relative abundances of bacterial populations not targeted by the bacteriophage(s) used.
[0095] Therapy provision in Block S17o can include provision of notifications to a user regarding the recommended therapy and/or other forms of therapy. Types of notifications and manners of providing notifications can be analogous to that described in U.S. App. No. 15/374,890 filed 09-DEC-2016, which is incorporated in its entirety by this reference.
[0096] As shown in FIGURE 4, the method 100 can additionally or alternatively include Block Si8o, which recites: monitoring effectiveness of the therapy for the user, based upon processing biological samples, to assess microbiome composition and/or functional diversity for the user over time. Block Si8o functions to gather additional data regarding positive effects, negative effects, and/or lack of effectiveness of a probiotic therapy suggested by the therapy model for users of a given characterization, where the additional data can be used, for example, to generate, update, and/or execute one or more characterization models, therapy models, and/or other suitable models. For example, the method loo can include updating a model (e.g., characterization model, therapy model, etc.) based one or more of a user microbiome composition dataset (e.g., features extracted from the dataset, etc.), a user microbiome functional diversity dataset (e.g., features extracted from the dataset, etc.), and/or other suitable dataset (e.g., updating a model based on modulation of the skin-related condition, determined based on comparisons of pre-therapy and post-therapy microbiome datasets); and in response to updating the model, determining an update (e.g., to a characterization, to a therapy, etc.) for a second user in relation to the skin-related condition, based on the updated model. In another example, the method loo can include: receiving a post-therapy biological sample from the user (e.g., after promoting the therapy);
generating a post-therapy characterization of the user in relation to the skin-related condition based on the post-therapy biological sample (e.g., post-therapy microbiome composition and/or functional diversity features extracted from the post-therapy biological sample using skin-related feature- selection rules, where the features can be used with a characterization model, etc.); characterizing modulation of the skin-related condition in relation to the user based on the post-therapy characterization (e.g., and one or more pre-therapy characterizations for the user, for a second user, etc.). However, any suitable portion of the method loo and/or any suitable operation can be performed in response to updating of models. Monitoring of a user during the course of a therapy promoted by the therapy model (e.g., by receiving and analyzing biological samples from the user throughout therapy, by receiving survey-derived data from the user throughout therapy) can thus be used to generate a therapy-effectiveness model for each characterization provided by the characterization process of Block S13o, and each recommended therapy measure provided in Blocks S14o and S17o.
[0097] In Block Si8o, the user can be prompted to provide additional biological samples at one or more key time points of a therapy regimen that incorporates the therapy, and the additional biological sample(s) can be processed and analyzed (e.g., in a manner similar to that described in relation to Block S12o) to generate metrics characterizing modulation of the user's microbiome composition and/or functional features.
For instance, metrics related to one or more of: a change in relative abundance of one or more taxonomic groups represented in the user's microbiome at an earlier time point, a change in representation of a specific taxonomic group of the user's microbiome, a ratio between abundance of a first taxonomic group of bacteria and abundance of a second taxonomic group of bacteria of the user's microbiome, a change in relative abundance of one or more functional families in a user's microbiome, and any other suitable metrics can be used to assess therapy effectiveness from changes in microbiome composition and/or functional features. Additionally or alternatively, survey-derived data from the user, pertaining to experiences of the user while on the therapy (e.g., experienced side effects, personal assessment of improvement, etc.) can be used to determine effectiveness of the therapy in Block Si80. However, monitoring effectiveness of one or more therapies can be performed in any suitable manner.
[0098] The method 100 can, however, include any other suitable blocks or steps configured to facilitate reception of biological samples from users, processing of biological samples from users, analyzing data derived from biological samples, and generating models that can be used to provide customized diagnostics and/or probiotic-based therapeutics according to specific microbiome compositions and/or functional features of users.
[0099] The method loo and/or system of the embodiments can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions. The instructions can be executed by computer-executable components integrated with the application, applet, host, server, network, website, communication service, communication interface, hardware/firmware/software elements of a patient computer or mobile device, or any suitable combination thereof. Other systems and methods of the embodiments can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions. The instructions can be executed by computer-executable components integrated by computer-executable components integrated with apparatuses and networks of the type described above. The computer-readable medium can be stored on any suitable computer readable media such as RAMs, ROMs, flash memory, EEPROMs, optical devices (CD or DVD), hard drives, floppy drives, or any suitable device. The computer-executable component can be a processor, though any suitable dedicated hardware device can (alternatively or additionally) execute the instructions.
[00100] The FIGURES illustrate the architecture, functionality and operation of possible implementations of systems, methods and computer program products according to preferred embodiments, example configurations, and variations thereof. In this regard, each block in the flowchart or block diagrams may represent a module, segment, step, or portion of code, which includes one or more executable instructions for implementing the specified logical function(s). It should also be noted that, in some alternative implementations, the functions noted in the block can occur out of the order noted in the FIGURES. For example, two blocks shown in succession may, in fact, be executed substantially concurrently, or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved. It will also be noted that each block of the block diagrams and/or flowchart illustration, and combinations of blocks in the block diagrams and/or flowchart illustration, can be implemented by special purpose hardware-based systems that perform the specified functions or acts, or combinations of special purpose hardware and computer instructions.
[00101] The embodiments include every combination and permutation of the various system components and the various method processes, including any variations, examples, and specific examples.
[00102] As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the embodiments of the invention without departing from the scope of this invention as defined in the following claims.
Claims (36)
1. A system for evaluating a skin-related condition in relation to a user, the system comprising:
.cndot. a handling network operable to collect containers comprising material from a set of users, the handling network comprising a sequencing system operable to determine microorganism sequences from sequencing the material;
.cndot. a microbiome characterization system operable to:
.cndot. determine microbiome composition data and microbiome functional diversity data based on the microorganism sequences, .cndot. collect supplementary data associated with the skin-related condition for the set of users, and .cndot. transform the supplementary data and features extracted from the microbiome composition data and the microbiome functional diversity data into a characterization model for the skin-related condition; and .cndot. a treatment system operable to promote a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
.cndot. a handling network operable to collect containers comprising material from a set of users, the handling network comprising a sequencing system operable to determine microorganism sequences from sequencing the material;
.cndot. a microbiome characterization system operable to:
.cndot. determine microbiome composition data and microbiome functional diversity data based on the microorganism sequences, .cndot. collect supplementary data associated with the skin-related condition for the set of users, and .cndot. transform the supplementary data and features extracted from the microbiome composition data and the microbiome functional diversity data into a characterization model for the skin-related condition; and .cndot. a treatment system operable to promote a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
2. The system of Claim 1, wherein the microbiome characterization system is further operable to:
.cndot. obtain a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and a subset of microbiome functional diversity features; and .cndot. generate the features based on evaluating the microbiome composition data and the microbiome functional diversity data against the set of skin-related feature-selection rules, wherein the set of skin-related feature selection rules are operable to improve the microbiome characterization system by facilitating decreased processing time to transform the supplementary data and the features into the characterization model.
.cndot. obtain a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and a subset of microbiome functional diversity features; and .cndot. generate the features based on evaluating the microbiome composition data and the microbiome functional diversity data against the set of skin-related feature-selection rules, wherein the set of skin-related feature selection rules are operable to improve the microbiome characterization system by facilitating decreased processing time to transform the supplementary data and the features into the characterization model.
3. The system of Claim 2, wherein the microbiome functional diversity features comprises at least one of: a cluster of orthologous group of proteins feature, a genomic functional feature, a taxonomic feature, a chemical functional feature, and a systemic functional feature.
4. The system of Claim 1, wherein the handling network further comprises a library preparation system operable to fragment and perform multiplex amplification on the material using a primer compatible with a genetic target associated with the skin-related condition.
5. The system of Claim 1, further comprising an interface operable to improve display of skin-related condition information derived from the characterization model, wherein the skin-related condition information comprises a microbiome composition for the user relative to a user group sharing a demographic characteristic, and wherein the microbiome composition comprises a set of taxa comprising at least one of: Marvinbryantia (genus), Erysipelotrichales (order), Erysipelotrichia (class), Bacteroidetes (phylum), Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), and Propionibacterium (genus).
6. The system of Claim 5, wherein the skin-related condition information comprises a change in the microbiome composition over time and a change in a microbiome functional diversity over time in relation to the treatment and the skin-related condition.
7. The system of Claim 1, wherein the functional features comprise at least one of a Kyoto Encyclopedia of Genes and Genomes (KEGG) functional feature and a Clusters of Orthologous Groups (COG) functional feature.
8. The system of Claim 7, wherein the features comprise transformation microbiome features derived from at least one of: a relative abundance monotonic transformation and a non-monotonic transformation.
9. The system of Claim 8, wherein the transformation microbiome features are associated with at least one of: a normalization, a feature vector derived at least one of linear latent variable analysis and non-linear latent variable analysis, linear regression, non-linear regression, a kernel method, a feature embedding method, machine learning, and a statistical inference method.
10. The system of Claim 7, wherein the skin-related condition comprises dry skin, and wherein the features comprise a microbiome composition feature associated with a relative abundance of at least one of: Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), and Propionibacterium (genus).
11. A method for characterizing a skin-related condition in relation to a first user, the method comprising:
.cndot. generating a microbiome composition dataset and a microbiome functional diversity dataset based on microorganism sequences derived from biological samples from a set of users;
.cndot. receiving a supplementary dataset informative of the skin-related condition for the set of users;
.cndot. obtaining a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and a subset of microbiome functional diversity features;
.cndot. generating a feature set based on evaluating the microbiome composition dataset and the microbiome functional diversity dataset against the set of skin-related feature-selection rules;
.cndot. applying the feature set with the supplementary dataset to generate a characterization model for the skin-related condition;
.cndot. generating a first characterization of the first user in relation to the skin-related condition using the characterization model; and .cndot. promoting a therapy to the first user for the skin-related condition based on the first characterization.
.cndot. generating a microbiome composition dataset and a microbiome functional diversity dataset based on microorganism sequences derived from biological samples from a set of users;
.cndot. receiving a supplementary dataset informative of the skin-related condition for the set of users;
.cndot. obtaining a set of skin-related feature-selection rules correlating the skin-related condition to a subset of microbiome composition features and a subset of microbiome functional diversity features;
.cndot. generating a feature set based on evaluating the microbiome composition dataset and the microbiome functional diversity dataset against the set of skin-related feature-selection rules;
.cndot. applying the feature set with the supplementary dataset to generate a characterization model for the skin-related condition;
.cndot. generating a first characterization of the first user in relation to the skin-related condition using the characterization model; and .cndot. promoting a therapy to the first user for the skin-related condition based on the first characterization.
12. The method of Claim 11, wherein the characterization model is an eczema-related characterization model, the method further comprising:
.cndot. generating a second feature set based on the microbiome composition dataset and the microbiome functional diversity dataset;
.cndot. applying the second feature set to generate a scalp-related characterization model; and .cndot. generating a second characterization of the first user in relation to a scalp-related condition using the scalp-related characterization model.
.cndot. generating a second feature set based on the microbiome composition dataset and the microbiome functional diversity dataset;
.cndot. applying the second feature set to generate a scalp-related characterization model; and .cndot. generating a second characterization of the first user in relation to a scalp-related condition using the scalp-related characterization model.
13. The method of Claim 12, further comprising:
.cndot. generating a third characterization of the first user in relation to a dry skin-related condition using a dry skin-related characterization model;
.cndot. wherein promoting the therapy to the first user comprises promoting the therapy based on the first, second, and third characterizations.
.cndot. generating a third characterization of the first user in relation to a dry skin-related condition using a dry skin-related characterization model;
.cndot. wherein promoting the therapy to the first user comprises promoting the therapy based on the first, second, and third characterizations.
14. The method of Claim 11, wherein promoting the therapy comprises automatically initiating a signal that controls a treatment system to promote the therapy based on the first characterization of the first user in relation to the skin-related condition.
15. The method of Claim 11, further comprising:
.cndot. generating a user microbiome composition feature for the first user based on a first skin-related feature-selection rule of the set of skin-related feature-selection rules;
and .cndot. generating a user microbiome functional diversity feature for the first user based on a second skin-related feature-selection rule of the set of skin-related feature-selection rules, wherein the first and the second skin-related feature-selection rules improve the characterization model, and .cndot. wherein generating the first characterization comprises generating the first characterization based on the user microbiome composition feature, the user microbiome functional diversity feature, and characterization model.
.cndot. generating a user microbiome composition feature for the first user based on a first skin-related feature-selection rule of the set of skin-related feature-selection rules;
and .cndot. generating a user microbiome functional diversity feature for the first user based on a second skin-related feature-selection rule of the set of skin-related feature-selection rules, wherein the first and the second skin-related feature-selection rules improve the characterization model, and .cndot. wherein generating the first characterization comprises generating the first characterization based on the user microbiome composition feature, the user microbiome functional diversity feature, and characterization model.
16. The method of Claim 15, .cndot. wherein the first characterization comprises a skin-related condition risk comprising at least one of an eczema risk, a dry skin risk, a scalp-related condition risk, a photosensitivity risk, and an acne risk, and the method further comprising:
.cndot. determining a cause for the skin-related condition risk based on the user microbiome composition feature and the user microbiome functional diversity feature; and .cndot. determining the therapy based on the cause, wherein the therapy is operable to reduce the skin-related condition risk.
.cndot. determining a cause for the skin-related condition risk based on the user microbiome composition feature and the user microbiome functional diversity feature; and .cndot. determining the therapy based on the cause, wherein the therapy is operable to reduce the skin-related condition risk.
17. The method of Claim 15, further comprising:
.cndot. updating the characterization model based on the user microbiome composition feature and the user microbiome functional diversity feature; and .cndot. in response to updating the characterization model, updating a second characterization for a second user in relation to the skin-related condition based on the updated characterization model.
.cndot. updating the characterization model based on the user microbiome composition feature and the user microbiome functional diversity feature; and .cndot. in response to updating the characterization model, updating a second characterization for a second user in relation to the skin-related condition based on the updated characterization model.
18. The method of Claim 11, further comprising:
.cndot. after promoting the therapy, receiving a post-therapy biological sample from the first user;
.cndot. generating a post-therapy characterization of the first user in relation to the skin-related condition based on the characterization model and the post-therapy biological sample; and .cndot. characterizing modulation of the skin-related condition in relation to the first user based on the post-therapy characterization and the characterization.
.cndot. after promoting the therapy, receiving a post-therapy biological sample from the first user;
.cndot. generating a post-therapy characterization of the first user in relation to the skin-related condition based on the characterization model and the post-therapy biological sample; and .cndot. characterizing modulation of the skin-related condition in relation to the first user based on the post-therapy characterization and the characterization.
19. The method of Claim 18, .cndot. wherein the therapy is operable to facilitate modification of a microbiome composition and a microbiome functional diversity of the first user, and the method further comprising:
.cndot. determining post-therapy user microbiome composition features and post-therapy microbiome functional diversity features based on the post-therapy biological sample and the set of skin-related feature-selection rules, wherein the post-therapy user microbiome composition features are associated with the subset of microbiome composition features, wherein the post-therapy microbiome functional diversity features are associated with the subset of microbiome functional diversity features, and .cndot. wherein generating the post-therapy characterization comprises generating the post-therapy characterization based on the post-therapy user microbiome composition features, the post-therapy microbiome functional diversity features, and the characterization model.
.cndot. determining post-therapy user microbiome composition features and post-therapy microbiome functional diversity features based on the post-therapy biological sample and the set of skin-related feature-selection rules, wherein the post-therapy user microbiome composition features are associated with the subset of microbiome composition features, wherein the post-therapy microbiome functional diversity features are associated with the subset of microbiome functional diversity features, and .cndot. wherein generating the post-therapy characterization comprises generating the post-therapy characterization based on the post-therapy user microbiome composition features, the post-therapy microbiome functional diversity features, and the characterization model.
20.The method of Claim 19, wherein the therapy is selected based on a therapy model, the method further comprising:
.cndot. updating the therapy model based on the modulation of the skin-related condition in relation to the first user;
.cndot. in response to updating the therapy model, updating a second therapy for a second user based on the updated therapy model; and .cndot. promoting the updated second therapy to the second user for the skin-related condition.
.cndot. updating the therapy model based on the modulation of the skin-related condition in relation to the first user;
.cndot. in response to updating the therapy model, updating a second therapy for a second user based on the updated therapy model; and .cndot. promoting the updated second therapy to the second user for the skin-related condition.
21. The method of Claim 11, further comprising:
.cndot. identifying a primer compatible with a genetic target associated with the skin-related condition, .cndot. amplifying nucleic acid material using the identified primer and a user biological sample from the first user; and .cndot. sequencing the nucleic acid material to determine user microorganism sequences, .cndot. wherein generating the first characterization for the first user comprises generating the first characterization based on the characterization model and the user microorganism sequences.
.cndot. identifying a primer compatible with a genetic target associated with the skin-related condition, .cndot. amplifying nucleic acid material using the identified primer and a user biological sample from the first user; and .cndot. sequencing the nucleic acid material to determine user microorganism sequences, .cndot. wherein generating the first characterization for the first user comprises generating the first characterization based on the characterization model and the user microorganism sequences.
22. The method of Claim 21, wherein identifying a primer compatible with a genetic target associated with the skin-related condition comprises identifying the primer based on the set of skin-related feature-selection rules.
23. The method of Claim 11, wherein the skin-related condition comprises Eczema, and wherein the subset of microbiome composition features comprises a composition feature associated with a set of taxa comprising at least one of:
Streptococcaceae, Streptococcus, Lactobacillales, and Veillonella.
Streptococcaceae, Streptococcus, Lactobacillales, and Veillonella.
24. The method of Claim 23, further comprising:
.cndot. determining a modulator of a biomolecule associated with the set of taxa and the skin-related condition;
.cndot. deriving a therapeutic composition for the skin-related condition based on the modulator, .cndot. wherein promoting the therapy comprises providing the therapeutic composition to the first user based on the characterization.
.cndot. determining a modulator of a biomolecule associated with the set of taxa and the skin-related condition;
.cndot. deriving a therapeutic composition for the skin-related condition based on the modulator, .cndot. wherein promoting the therapy comprises providing the therapeutic composition to the first user based on the characterization.
25. The method of Claim 23, wherein the subset of microbiome functional diversity features comprises at least one of a Kyoto Encyclopedia of Genes and Genomes (KEGG) functional feature and a Clusters of Orthologous Groups (COG) functional feature.
26. The method of Claim 23, wherein the composition feature for a single microorganism is associated with at least one of the following metrics:
relative abundance, differential relative abundance, presence, and absence.
relative abundance, differential relative abundance, presence, and absence.
27. The method of Claim 11, wherein the skin-related condition comprises a scalp-related condition including dandruff, and wherein the subset of microbiome composition features comprises a variety of features associated with a set of taxa comprising and including at least one of: Propionibacterium sp. M5P09A
(species), Bacteroides vulgatus (species, Streptococcus sp. BS35a (species), Staphylococcus sp.
C9I2 (species), Phascolarctobacterium sp. 377 (species), Faecalibacterium prausnitzii (species), Alistipes putredinis (species), Alistipes sp. EBA6-25c12 (species), Alistipes sp. RMA 9912 (species) Anaerostipes sp. 5 1 63FA
(species), Bacteroides acidifaciens (species), Bacteroides caccae (species), Bacteroides fragilis (species), Bacteroides plebeius (species), Bacteroides sp. AR2o (species), Bacteroides sp. AR29 (species), Bacteroides sp. D22 (species), Bacteroides sp. DJF
(species), Bacteroides sp. SLC1-38 (species), Bacteroides sp. XB12B (species), Bacteroides vulgatus (species), Blautia faecis (species), Blautia luti (species), Blautia sp. YHC-4 (species), Blautia stercoris (species), Blautia wexlerae (species), Collinsella aerofaciens (species), Corynebacterium sp. (species), Corynebacterium spheniscorum (species), Corynebacterium ulcerans (species), Dorea formicigenerans (species), Dorea longicatena (species), Lachnospira pectinoschiza (species), Odoribacter splanchnicus (species), Parabacteroides distasonis (species), Parabacteroides merdae (species), Phascolarctobacterium faecium (species), Propionibacterium acnes (species), Propionibacterium granulosum (species), Propionibacterium sp. M5P09A (species), Roseburia intestinalis (species), Roseburia inulinivorans (species), Roseburia sp. 115E39 (species), Staphylococcus sp.
(species), Staphylococcus sp. WB18-16 (species), Streptococcus sp. BS35a (species), Streptococcus sp. oral taxon G59 (species), Streptococcus thermophilus (species), Subdoligranulum variabile (species), Sutterella stercoricanis (species), Sutterella wadsworthensis Propionibacterium (genus), Staphylococcus (genus), Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Bifidobacterium (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Dialister (genus), Prevotella (genus), Marvinbryantia (genus), Propionibacteriaceae (family), Staphylococcaceae (family), Porphyromonadaceae (family), Lachnospiraceae (family), Peptostreptococcaceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Bifidobacteriaceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Actinomycetales (order), Selenomonadales (order), Bacillales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Bifidobacteriales (order), Pasteurellales (order), Actinobacteria (class), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Bacilli (class), Deltaproteobacteria (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Actinobacteria (phylum), Proteobacteria (phylum), Firmicutes (phylum), and Verrucomicrobia (phylum).
(species), Bacteroides vulgatus (species, Streptococcus sp. BS35a (species), Staphylococcus sp.
C9I2 (species), Phascolarctobacterium sp. 377 (species), Faecalibacterium prausnitzii (species), Alistipes putredinis (species), Alistipes sp. EBA6-25c12 (species), Alistipes sp. RMA 9912 (species) Anaerostipes sp. 5 1 63FA
(species), Bacteroides acidifaciens (species), Bacteroides caccae (species), Bacteroides fragilis (species), Bacteroides plebeius (species), Bacteroides sp. AR2o (species), Bacteroides sp. AR29 (species), Bacteroides sp. D22 (species), Bacteroides sp. DJF
(species), Bacteroides sp. SLC1-38 (species), Bacteroides sp. XB12B (species), Bacteroides vulgatus (species), Blautia faecis (species), Blautia luti (species), Blautia sp. YHC-4 (species), Blautia stercoris (species), Blautia wexlerae (species), Collinsella aerofaciens (species), Corynebacterium sp. (species), Corynebacterium spheniscorum (species), Corynebacterium ulcerans (species), Dorea formicigenerans (species), Dorea longicatena (species), Lachnospira pectinoschiza (species), Odoribacter splanchnicus (species), Parabacteroides distasonis (species), Parabacteroides merdae (species), Phascolarctobacterium faecium (species), Propionibacterium acnes (species), Propionibacterium granulosum (species), Propionibacterium sp. M5P09A (species), Roseburia intestinalis (species), Roseburia inulinivorans (species), Roseburia sp. 115E39 (species), Staphylococcus sp.
(species), Staphylococcus sp. WB18-16 (species), Streptococcus sp. BS35a (species), Streptococcus sp. oral taxon G59 (species), Streptococcus thermophilus (species), Subdoligranulum variabile (species), Sutterella stercoricanis (species), Sutterella wadsworthensis Propionibacterium (genus), Staphylococcus (genus), Roseburia (genus), Blautia (genus), Bacteroides (genus), Pseudobutyrivibrio (genus), Alistipes (genus), Faecalibacterium (genus), Collinsella (genus), Clostridium (genus), Anaerostipes (genus), Dorea (genus), Subdoligranulum (genus), Sarcina (genus), Lachnospira (genus), Anaerotruncus (genus), Parabacteroides (genus), Flavonifractor (genus), Intestinibacter (genus), Erysipelatoclostridium (genus), Phascolarctobacterium (genus), Streptococcus (genus), Odoribacter (genus), Sutterella (genus), Bifidobacterium (genus), Corynebacterium (genus), Bilophila (genus), Terrisporobacter (genus), Dialister (genus), Prevotella (genus), Marvinbryantia (genus), Propionibacteriaceae (family), Staphylococcaceae (family), Porphyromonadaceae (family), Lachnospiraceae (family), Peptostreptococcaceae (family), Coriobacteriaceae (family), Clostridiaceae (family), Ruminococcaceae (family), Bacteroidaceae (family), Erysipelotrichaceae (family), Rikenellaceae (family), Prevotellaceae (family), Sutterellaceae (family), Flavobacteriaceae (family), Streptococcaceae (family), Veillonellaceae (family), Acidaminococcaceae (family), Desulfovibrionaceae (family), Oscillospiraceae (family), Bifidobacteriaceae (family), Corynebacteriaceae (family), Pasteurellaceae (family), Bacteroidales (order), Actinomycetales (order), Selenomonadales (order), Bacillales (order), Coriobacteriales (order), Clostridiales (order), Erysipelotrichales (order), Lactobacillales (order), Burkholderiales (order), Flavobacteriales (order), Desulfovibrionales (order), Bifidobacteriales (order), Pasteurellales (order), Actinobacteria (class), Bacteroidia (class), Negativicutes (class), Betaproteobacteria (class), Clostridia (class), Erysipelotrichia (class), Flavobacteriia (class), Bacilli (class), Deltaproteobacteria (class), Gammaproteobacteria (class), Bacteroidetes (phylum), Actinobacteria (phylum), Proteobacteria (phylum), Firmicutes (phylum), and Verrucomicrobia (phylum).
28.The method of Claim 27, wherein the subset of microbiome functional diversity features comprises a Kyoto Encyclopedia of Genes and Genomes (KEGG) functional features associated with at least one of: a glycan biosynthesis and metabolism KEGG
L2 derived feature, an environmental adaptation KEGG L2 derived feature, a cancers KEGG L2 derived feature, an immune system diseases KEGG L2 derived feature, a transcription KEGG L2 derived feature, a signaling molecules and interaction KEGG
L2 derived feature, a membrane transport KEGG L2 derived feature, a cell motility KEGG L2 derived feature, a cellular processes and signaling KEGG L2 derived feature, a metabolism of cofactors and vitamins KEGG L2 derived feature, a metabolism KEGG L2 derived feature, a neurodegenerative diseases KEGG L2 derived feature, a metabolic diseases KEGG L2 derived feature, an enzyme families KEGG L2 derived feature, a cell growth and death KEGG L2 derived feature, a carbohydrate metabolism KEGG L2 derived feature, a transport and catabolism KEGG L2 derived feature, a genetic information processing KEGG L2 derived feature, a replication and repair KEGG L2 derived feature, an energy metabolism KEGG L2 derived feature, a digestive system KEGG L2 derived feature, an amino acid metabolism KEGG L2 derived feature, a metabolism of other amino acids KEGG
L2 derived feature, a biosynthesis of other secondary metabolites KEGG L2 derived feature, a folding, sorting and degradation KEGG L2 derived feature, a lipid metabolism KEGG L2 derived feature, an infectious diseases KEGG L2 derived feature, a nucleotide metabolism KEGG L2 derived feature, a metabolism of terpenoids and polyketides KEGG L2 derived feature, a renal cell carcinoma KEGG
L3 derived feature, an ubiquinone and other terpenoid-quinone biosynthesis KEGG
L3 derived feature, an amyotrophic lateral sclerosis KEGG L3 derived feature, a lipoic acid metabolism KEGG L3 derived feature, a cyanoamino acid metabolism KEGG L3 derived feature, a glutathione metabolism KEGG L3 derived feature, a toluene degradation KEGG L3 derived feature, a riboflavin metabolism KEGG L3 derived feature, a plant-pathogen interaction KEGG L3 derived feature, a prenyltransferases KEGG L3 derived feature, a biosynthesis of ansamycins KEGG
derived feature, an ABC transporters KEGG L3 derived feature, an inositol phosphate metabolism KEGG L3 derived feature, a citrate cycle (TCA cycle) KEGG
L3 derived feature, a chromosome KEGG L3 derived feature, a glycolysis /
gluconeogenesis KEGG L3 derived feature, a valine, leucine and isoleucine degradation KEGG L3 derived feature, a primary immunodeficiency KEGG L3 derived feature, a DNA replication proteins KEGG L3 derived feature, a cytoskeleton proteins KEGG L3 derived feature, a peroxisome KEGG L3 derived feature, a transcription machinery KEGG L3 derived feature, a protein folding and associated processing KEGG L3 derived feature, a d-alanine metabolism KEGG L3 derived feature, a translation proteins KEGG L3 derived feature, a glycine, serine and threonine metabolism KEGG L3 derived feature, a lipopolysaccharide biosynthesis proteins KEGG L3 derived feature, an energy metabolism KEGG L3 derived feature, a lipid metabolism KEGG L3 derived feature, a peptidases KEGG L3 derived feature, a carbohydrate digestion and absorption KEGG L3 derived feature, a caprolactam degradation KEGG L3 derived feature, a glycerolipid metabolism KEGG L3 derived feature, a carbon fixation in photosynthetic organisms KEGG L3 derived feature, a membrane and intracellular structural molecules KEGG L3 derived feature, a fatty acid biosynthesis KEGG L3 derived feature, a type I diabetes mellitus KEGG L3 derived feature, a phosphotransferase system (pts) KEGG L3 derived feature, a base excision repair KEGG L3 derived feature, a sporulation KEGG L3 derived feature, a transporters KEGG L3 derived feature, a protein kinases KEGG L3 derived feature, a pantothenate and CoA biosynthesis KEGG L3 derived feature, a cell cycle -Caulobacter KEGG L3 derived feature, a butirosin and neomycin biosynthesis KEGG
L3 derived feature, a mismatch repair KEGG L3 derived feature, a pores ion channels KEGG L3 derived feature, an oxidative phosphorylation KEGG L3 derived feature, a cell division KEGG L3 derived feature, a replication, recombination and repair proteins KEGG L3 derived feature, a bacterial motility proteins KEGG L3 derived feature, a carbon fixation pathways in prokaryotes KEGG L3 derived feature, a transcription factors KEGG L3 derived feature, a vitamin b6 metabolism KEGG L3 derived feature, a chloroalkane and chloroalkene degradation KEGG L3 derived feature, a peptidoglycan biosynthesis KEGG L3 derived feature, a drug metabolism -other enzymes KEGG L3 derived feature, a proteasome KEGG L3 derived feature, a RNA transport KEGG L3 derived feature, an ascorbate and aldarate metabolism KEGG L3 derived feature, a cysteine and methionine metabolism KEGG L3 derived feature, a galactose metabolism KEGG L3 derived feature, a tetracycline biosynthesis KEGG L3 derived feature, a translation factors KEGG L3 derived feature, a glycerophospholipid metabolism KEGG L3 derived feature, a pentose phosphate pathway KEGG L3 derived feature, a tyrosine metabolism KEGG L3 derived feature, a photosynthesis proteins KEGG L3 derived feature, a Vibrio cholerae pathogenic cycle KEGG L3 derived feature, an amino sugar and nucleotide sugar metabolism KEGG L3 derived feature, a bacterial chemotaxis KEGG L3 derived feature, a tryptophan metabolism KEGG L3 derived feature, a nicotinate and nicotinamide metabolism KEGG L3 derived feature, a histidine metabolism KEGG L3 derived feature, a biotin metabolism KEGG L3 derived feature, a secretion system KEGG
derived feature, a cellular antigens KEGG L3 derived feature, a sulfur relay system KEGG L3 derived feature, a taurine and hypotaurine metabolism KEGG L3 derived feature, a photosynthesis KEGG L3 derived feature, a zeatin biosynthesis KEGG
derived feature, a methane metabolism KEGG L3 derived feature, a RNA
degradation KEGG L3 derived feature, a phosphatidylinositol signaling system KEGG L3 derived feature, a glyoxylate and dicarboxylate metabolism KEGG L3 derived feature, an adipocytokine signaling pathway KEGG L3 derived feature, a starch and sucrose metabolism KEGG L3 derived feature, a chaperones and folding catalysts KEGG L3 derived feature, a vitamin metabolism KEGG L3 derived feature, a pyruvate metabolism KEGG L3 derived feature, a porphyrin and chlorophyll metabolism KEGG L3 derived feature, a geraniol degradation KEGG L3 derived feature, a tuberculosis KEGG L3 derived feature, a tropane, piperidine and pyridine alkaloid biosynthesis KEGG L3 derived feature, a beta-alanine metabolism KEGG
derived feature, a PPAR signaling pathway KEGG L3 derived feature, a lysine biosynthesis KEGG L3 derived feature, a protein export KEGG L3 derived feature, an arachidonic acid metabolism KEGG L3 derived feature, a thiamine metabolism KEGG L3 derived feature, a phenylpropanoid biosynthesis KEGG L3 derived feature, a ribosome biogenesis KEGG L3 derived feature, a nucleotide excision repair KEGG
L3 derived feature, a synthesis and degradation of ketone bodies KEGG L3 derived feature, a benzoate degradation KEGG L3 derived feature, a sulfur metabolism KEGG L3 derived feature, a metabolism of xenobiotics by cytochrome p450 KEGG
L3 derived feature, a penicillin and cephalosporin biosynthesis KEGG L3 derived feature, a drug metabolism - cytochrome p45o KEGG L3 derived feature, a purine metabolism KEGG L3 derived feature, a novobiocin biosynthesis KEGG L3 derived feature, a propanoate metabolism KEGG L3 derived feature, a limonene and pinene degradation KEGG L3 derived feature, an aminobenzoate degradation KEGG L3 derived feature, a Huntington's disease KEGG L3 derived feature, a C5-branched dibasic acid metabolism KEGG L3 derived feature, a folate biosynthesis KEGG L3 derived feature, and a phenylalanine metabolism KEGG L3 derived feature.
L2 derived feature, an environmental adaptation KEGG L2 derived feature, a cancers KEGG L2 derived feature, an immune system diseases KEGG L2 derived feature, a transcription KEGG L2 derived feature, a signaling molecules and interaction KEGG
L2 derived feature, a membrane transport KEGG L2 derived feature, a cell motility KEGG L2 derived feature, a cellular processes and signaling KEGG L2 derived feature, a metabolism of cofactors and vitamins KEGG L2 derived feature, a metabolism KEGG L2 derived feature, a neurodegenerative diseases KEGG L2 derived feature, a metabolic diseases KEGG L2 derived feature, an enzyme families KEGG L2 derived feature, a cell growth and death KEGG L2 derived feature, a carbohydrate metabolism KEGG L2 derived feature, a transport and catabolism KEGG L2 derived feature, a genetic information processing KEGG L2 derived feature, a replication and repair KEGG L2 derived feature, an energy metabolism KEGG L2 derived feature, a digestive system KEGG L2 derived feature, an amino acid metabolism KEGG L2 derived feature, a metabolism of other amino acids KEGG
L2 derived feature, a biosynthesis of other secondary metabolites KEGG L2 derived feature, a folding, sorting and degradation KEGG L2 derived feature, a lipid metabolism KEGG L2 derived feature, an infectious diseases KEGG L2 derived feature, a nucleotide metabolism KEGG L2 derived feature, a metabolism of terpenoids and polyketides KEGG L2 derived feature, a renal cell carcinoma KEGG
L3 derived feature, an ubiquinone and other terpenoid-quinone biosynthesis KEGG
L3 derived feature, an amyotrophic lateral sclerosis KEGG L3 derived feature, a lipoic acid metabolism KEGG L3 derived feature, a cyanoamino acid metabolism KEGG L3 derived feature, a glutathione metabolism KEGG L3 derived feature, a toluene degradation KEGG L3 derived feature, a riboflavin metabolism KEGG L3 derived feature, a plant-pathogen interaction KEGG L3 derived feature, a prenyltransferases KEGG L3 derived feature, a biosynthesis of ansamycins KEGG
derived feature, an ABC transporters KEGG L3 derived feature, an inositol phosphate metabolism KEGG L3 derived feature, a citrate cycle (TCA cycle) KEGG
L3 derived feature, a chromosome KEGG L3 derived feature, a glycolysis /
gluconeogenesis KEGG L3 derived feature, a valine, leucine and isoleucine degradation KEGG L3 derived feature, a primary immunodeficiency KEGG L3 derived feature, a DNA replication proteins KEGG L3 derived feature, a cytoskeleton proteins KEGG L3 derived feature, a peroxisome KEGG L3 derived feature, a transcription machinery KEGG L3 derived feature, a protein folding and associated processing KEGG L3 derived feature, a d-alanine metabolism KEGG L3 derived feature, a translation proteins KEGG L3 derived feature, a glycine, serine and threonine metabolism KEGG L3 derived feature, a lipopolysaccharide biosynthesis proteins KEGG L3 derived feature, an energy metabolism KEGG L3 derived feature, a lipid metabolism KEGG L3 derived feature, a peptidases KEGG L3 derived feature, a carbohydrate digestion and absorption KEGG L3 derived feature, a caprolactam degradation KEGG L3 derived feature, a glycerolipid metabolism KEGG L3 derived feature, a carbon fixation in photosynthetic organisms KEGG L3 derived feature, a membrane and intracellular structural molecules KEGG L3 derived feature, a fatty acid biosynthesis KEGG L3 derived feature, a type I diabetes mellitus KEGG L3 derived feature, a phosphotransferase system (pts) KEGG L3 derived feature, a base excision repair KEGG L3 derived feature, a sporulation KEGG L3 derived feature, a transporters KEGG L3 derived feature, a protein kinases KEGG L3 derived feature, a pantothenate and CoA biosynthesis KEGG L3 derived feature, a cell cycle -Caulobacter KEGG L3 derived feature, a butirosin and neomycin biosynthesis KEGG
L3 derived feature, a mismatch repair KEGG L3 derived feature, a pores ion channels KEGG L3 derived feature, an oxidative phosphorylation KEGG L3 derived feature, a cell division KEGG L3 derived feature, a replication, recombination and repair proteins KEGG L3 derived feature, a bacterial motility proteins KEGG L3 derived feature, a carbon fixation pathways in prokaryotes KEGG L3 derived feature, a transcription factors KEGG L3 derived feature, a vitamin b6 metabolism KEGG L3 derived feature, a chloroalkane and chloroalkene degradation KEGG L3 derived feature, a peptidoglycan biosynthesis KEGG L3 derived feature, a drug metabolism -other enzymes KEGG L3 derived feature, a proteasome KEGG L3 derived feature, a RNA transport KEGG L3 derived feature, an ascorbate and aldarate metabolism KEGG L3 derived feature, a cysteine and methionine metabolism KEGG L3 derived feature, a galactose metabolism KEGG L3 derived feature, a tetracycline biosynthesis KEGG L3 derived feature, a translation factors KEGG L3 derived feature, a glycerophospholipid metabolism KEGG L3 derived feature, a pentose phosphate pathway KEGG L3 derived feature, a tyrosine metabolism KEGG L3 derived feature, a photosynthesis proteins KEGG L3 derived feature, a Vibrio cholerae pathogenic cycle KEGG L3 derived feature, an amino sugar and nucleotide sugar metabolism KEGG L3 derived feature, a bacterial chemotaxis KEGG L3 derived feature, a tryptophan metabolism KEGG L3 derived feature, a nicotinate and nicotinamide metabolism KEGG L3 derived feature, a histidine metabolism KEGG L3 derived feature, a biotin metabolism KEGG L3 derived feature, a secretion system KEGG
derived feature, a cellular antigens KEGG L3 derived feature, a sulfur relay system KEGG L3 derived feature, a taurine and hypotaurine metabolism KEGG L3 derived feature, a photosynthesis KEGG L3 derived feature, a zeatin biosynthesis KEGG
derived feature, a methane metabolism KEGG L3 derived feature, a RNA
degradation KEGG L3 derived feature, a phosphatidylinositol signaling system KEGG L3 derived feature, a glyoxylate and dicarboxylate metabolism KEGG L3 derived feature, an adipocytokine signaling pathway KEGG L3 derived feature, a starch and sucrose metabolism KEGG L3 derived feature, a chaperones and folding catalysts KEGG L3 derived feature, a vitamin metabolism KEGG L3 derived feature, a pyruvate metabolism KEGG L3 derived feature, a porphyrin and chlorophyll metabolism KEGG L3 derived feature, a geraniol degradation KEGG L3 derived feature, a tuberculosis KEGG L3 derived feature, a tropane, piperidine and pyridine alkaloid biosynthesis KEGG L3 derived feature, a beta-alanine metabolism KEGG
derived feature, a PPAR signaling pathway KEGG L3 derived feature, a lysine biosynthesis KEGG L3 derived feature, a protein export KEGG L3 derived feature, an arachidonic acid metabolism KEGG L3 derived feature, a thiamine metabolism KEGG L3 derived feature, a phenylpropanoid biosynthesis KEGG L3 derived feature, a ribosome biogenesis KEGG L3 derived feature, a nucleotide excision repair KEGG
L3 derived feature, a synthesis and degradation of ketone bodies KEGG L3 derived feature, a benzoate degradation KEGG L3 derived feature, a sulfur metabolism KEGG L3 derived feature, a metabolism of xenobiotics by cytochrome p450 KEGG
L3 derived feature, a penicillin and cephalosporin biosynthesis KEGG L3 derived feature, a drug metabolism - cytochrome p45o KEGG L3 derived feature, a purine metabolism KEGG L3 derived feature, a novobiocin biosynthesis KEGG L3 derived feature, a propanoate metabolism KEGG L3 derived feature, a limonene and pinene degradation KEGG L3 derived feature, an aminobenzoate degradation KEGG L3 derived feature, a Huntington's disease KEGG L3 derived feature, a C5-branched dibasic acid metabolism KEGG L3 derived feature, a folate biosynthesis KEGG L3 derived feature, and a phenylalanine metabolism KEGG L3 derived feature.
29. The method of Claim 27, wherein the composition feature for a single microorganism is associated with at least one of the following metrics: relative abundance, differential relative abundance, presence, and absence.
30.The method of Claim 11, wherein the skin-related condition comprises dry skin, and wherein the subset of microbiome composition features comprises a composition feature associated with a set of taxa including at least one of:
Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), and Propionibacterium (genus).
Staphylococcus (genus), Staphylococcaceae (family), Bacillales (order), Actinobacteria (class), Firmicutes (phylum), Actinobacteria (phylum), and Propionibacterium (genus).
31. The method of Claim 30, wherein the subset of microbiome functional diversity features comprises at least one of a Kyoto Encyclopedia of Genes and Genomes (KEGG) functional feature and a Clusters of Orthologous Groups (COG) functional feature.
32. The method of Claim 23, wherein the composition feature for a single microorganism is associated with at least one of the following metrics:
relative abundance, differential relative abundance, presence, and absence.
relative abundance, differential relative abundance, presence, and absence.
33. The method of Claim 11, wherein the skin-related condition comprises photosensitivity, and wherein the subset of microbiome composition features comprises a composition feature associated with a set of taxa comprising at least one of: Marvinbryantia (genus), Erysipelotrichales (order), Erysipelotrichia (class), and Bacteroidetes (phylum).
34. The method of Claim 33, wherein the subset of microbiome functional diversity features comprises an infectious diseases KEGG L2 derived feature.
35. The method of Claim 33, wherein the composition feature for a single microorganism is associated with at least one of the following metrics:
relative abundance, differential relative abundance, presence, and absence.
relative abundance, differential relative abundance, presence, and absence.
36. The method of Claim 11, wherein the skin-related condition comprises a pimple-related condition, and wherein the subset of microbiome composition features comprises a composition feature associated with a set of taxa comprising Lactobacillales.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662327048P | 2016-04-25 | 2016-04-25 | |
US201662327126P | 2016-04-25 | 2016-04-25 | |
US201662327089P | 2016-04-25 | 2016-04-25 | |
US62/327,126 | 2016-04-25 | ||
US62/327,048 | 2016-04-25 | ||
US62/327,089 | 2016-04-25 | ||
PCT/US2017/029470 WO2017189614A1 (en) | 2016-04-25 | 2017-04-25 | Method and system for characterizing skin related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3022294A1 true CA3022294A1 (en) | 2017-11-02 |
Family
ID=60160002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3022294A Pending CA3022294A1 (en) | 2016-04-25 | 2017-04-25 | Method and system for characterizing skin-related conditions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3448399A4 (en) |
CN (1) | CN109152803B (en) |
AU (1) | AU2017257785A1 (en) |
CA (1) | CA3022294A1 (en) |
WO (1) | WO2017189614A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160048760A (en) | 2013-06-18 | 2016-05-04 | 프로더믹, 인코포레이티드 | Customized skin care products and personal care products based on the analysis of skin flora |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
US11926876B2 (en) | 2017-03-10 | 2024-03-12 | Prodermiq, Inc. | Customized skin care products and personal care products based on the analysis of skin flora |
EP3775263A4 (en) * | 2018-03-26 | 2021-09-22 | Prodermiq, Inc. | Compositions and methods for the treatment of acne |
WO2019191409A1 (en) * | 2018-03-29 | 2019-10-03 | Kimberly-Clark Worldwide, Inc. | Sensor for indicating a potential forthcoming skin or gastrointestinal issue and methods of using the same |
EP4367258A1 (en) * | 2021-07-05 | 2024-05-15 | Unilever IP Holdings B.V. | Method for assessing skin |
BR112023026959A2 (en) * | 2021-07-05 | 2024-03-12 | Unilever Ip Holdings B V | METHODS FOR EVALUATING A COSMETIC COMPOSITION, PREPARING A WRITABLE MEDIUM FOR DEMONSTRATING THE RESULT OF EVALUATING A COSMETIC COMPOSITION AND DEMONSTRATING THE RESULT OF EVALUATING A COSMETIC COMPOSITION |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
CN107936121B (en) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | Multispecific FAB fusion proteins and methods of use thereof |
SG11201405783VA (en) * | 2012-03-17 | 2014-10-30 | Univ California | Fast diagnosis and personalized treatments for acne |
US10131710B2 (en) * | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
MX2015010843A (en) * | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules. |
EP2968552B1 (en) * | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
KR20160048760A (en) * | 2013-06-18 | 2016-05-04 | 프로더믹, 인코포레이티드 | Customized skin care products and personal care products based on the analysis of skin flora |
KR102649364B1 (en) * | 2013-11-07 | 2024-03-20 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cell-free nucleic acids for the analysis of the human microbiome and components thereof |
CA2936933C (en) * | 2014-01-25 | 2024-05-21 | uBiome, Inc. | Method and system for microbiome analysis |
CA2962466C (en) * | 2014-10-21 | 2023-01-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
EP3283084A4 (en) * | 2015-04-13 | 2018-12-19 | Ubiome Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
EP3426794A4 (en) * | 2016-03-07 | 2019-11-13 | Ubiome, Inc. | Method and system for characterizing mouth-associated conditions |
-
2017
- 2017-04-25 EP EP17790288.9A patent/EP3448399A4/en active Pending
- 2017-04-25 CA CA3022294A patent/CA3022294A1/en active Pending
- 2017-04-25 WO PCT/US2017/029470 patent/WO2017189614A1/en active Application Filing
- 2017-04-25 AU AU2017257785A patent/AU2017257785A1/en active Pending
- 2017-04-25 CN CN201780030413.6A patent/CN109152803B/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3448399A1 (en) | 2019-03-06 |
EP3448399A4 (en) | 2020-05-13 |
AU2017257785A1 (en) | 2018-11-08 |
CN109152803A (en) | 2019-01-04 |
CN109152803B (en) | 2022-09-23 |
WO2017189614A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10169541B2 (en) | Method and systems for characterizing skin related conditions | |
US10381117B2 (en) | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions | |
US10327641B2 (en) | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features | |
US10786194B2 (en) | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features | |
US10787714B2 (en) | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features | |
US10366793B2 (en) | Method and system for characterizing microorganism-related conditions | |
US10902938B2 (en) | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions | |
US10246753B2 (en) | Method and system for characterizing mouth-associated conditions | |
US10381112B2 (en) | Method and system for characterizing allergy-related conditions associated with microorganisms | |
CA3022294A1 (en) | Method and system for characterizing skin-related conditions | |
US20170235902A1 (en) | Method and system for characterization of clostridium difficile associated conditions | |
AU2022200243A1 (en) | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions | |
AU2022203347A1 (en) | Method and system for microbiome-derived characterization, diaganostics and therapeutics for conditions associated with functional features | |
AU2016366656A1 (en) | Method and system for characterization of Clostridium difficile-associated conditions | |
WO2018112459A1 (en) | Method and system for characterizing microorganism-related conditions | |
EP3775257A1 (en) | Method and system for characterizing allergy-related conditions associated with microorganisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20211129 |
|
EEER | Examination request |
Effective date: 20211129 |
|
EEER | Examination request |
Effective date: 20211129 |
|
EEER | Examination request |
Effective date: 20211129 |
|
EEER | Examination request |
Effective date: 20211129 |
|
EEER | Examination request |
Effective date: 20211129 |